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spondylitis	 (AS),	non-radiographic	axial	 SpA	 (nr-axSpA),	psoriatic	 arthritis	 (PsA),	 SpA	 related	 to	 IBD	
(IBD-SpA),	reactive	arthritis	(ReA)	and	undifferentiated	SpA	(uSpA).2	Until	the	1950s	it	was	believed	
that	 there	was	no	distinction	between	the	different	 types	of	arthritis	 like	 rheumatoid	arthritis	and	
spondyloarthritis.	Afterwards,	 the	discussion	started	 that	SpA	may	be	an	entirely	different	disease	
than	rheumatoid	arthritis.	In	1976,	Moll	&	Wright	were	the	first	to	describe	the	unified	concept	of	SpA	
characterized	 as	 seronegative	 arthritides,	 with	 overlapping	 clinical,	 serological	 and	 radiological	
features.3		After	the	concept	of	SpA	was	established,	the	development	of	classification	criteria	started.	
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in	1990,	 followed	by	 the	ESSG	criteria	 in	1991.4,5	The	AMOR	criteria	consist	of	a	 scoring	system	of	
different	signs	and	symptoms	of	SpA,	which	can	contribute	either	1,	2	or	3	points	to	the	required	6	for	
classifying	 SpA.4	 To	 fulfil	 the	 ESSG	 criteria	 a	 patient	 must	 have	 inflammatory	 back	 pain	 and/or	
peripheral	arthritis,	 in	combination	with	one	other	SpA	feature.5	These	criteria	seemed	to	perform	
reasonable	in	different	cohorts,	but	the	main	problem	was	the	low	sensitivity	for	early	SpA.	In	addition,	




















































Psoriasis	 is	a	chronic	 immune-mediated	disease	of	 the	skin,	 leading	to	characteristic	erythematous	
plaques.19	It	affects	men	and	women	equally	and	can	occur	at	any	age	with	peak	incidence	between	
20-30	 years	 of	 age	 and	 50-60	 years	 of	 age.20	 Psoriasis	 can	 be	 accompanied	 by	 a	 number	 of	
comorbidities,	 including	cardiovascular	disease,	depression	and	as	described	 in	this	 thesis	psoriatic	




occurs	 in	 an	 asymmetrical	 distribution	 and	mostly	 in	 the	 larger	 joints,	 but	 there	 is	 also	 a	 subtype	
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the	bone,	but	 the	most	known	 location	 is	 the	Achilles	 tendon.	Another	subtype	of	PsA	 is	 the	axial	
subtype,	with	inflammation	of	the	sacroiliac	joints,	like	ankylosing	spondylitis.	It	has	been	described	
that	 certain	 factors	 in	 psoriasis	 patients	 are	 associated	 with	 the	 development	 of	 PsA.	 These	
characteristics	 include	 psoriasis	 of	 the	 nail,	 scalp	 or	 intergluteal	 as	 well	 as	 certain	 environmental	
factors	 like	 infections,	 heavy	 lifting	 and	 injuries.23,24	 Over	 the	 years,	multiple	 sets	 of	 classification	
criteria	have	been	developed	and	used	for	PsA.	One	of	the	first	is	by	Moll	&	Wright,	who	divided	PsA	
into	five	clinical	patterns;	asymmetrical	oligoarthritis,	symmetrical	polyarthritis,	distal	interphalangeal	
arthritis,	 arthritis	 mutilans	 and	 spinal	 column	 involvement.25	 As	 the	 pattern	 of	 involvement	 may	
change	over	time,	this	classification	proved	not	very	useful.22	In	2006	the	now	widely	used	CASPAR	
criteria	were	 introduced.26	 To	 fulfil	 these	 classification	 criteria,	 a	 patient	must	 have	 inflammatory	
articular,	 entheseal	 or	 spinal	 disease.	 On	 top	 of	 this,	 at	 least	 3	 out	 of	 the	 following	 6	 points	 are	
required:	the	presence	of	psoriasis	(current	(2	points)	or	history),	presence	of	psoriatic	nail	dystrophy,	
absence	of	rheumatoid	factor,	dactylitis	(diagnosed	by	rheumatologist)	and	radiographic	evidence	of	
juxtaarticular	 new	 bone	 formation.	 The	 difficulty	 with	 these	 criteria	 is	 that	 the	 stem	 elements	
(inflammatory	articular,	entheseal	or	spinal	disease)	are	not	defined.	Whereas	this	might	be	less	of	a	
problem	for	articular	and	spinal	disease,	the	definition	of	inflammatory	entheseal	disease	is	not	clear.	































treatments.	 Specific	 treatment	 for	 psoriasis	 includes	 topical	 treatment	 (including	 steroids),	
phototherapy	and	oral	retinoids.41	For	severe	psoriasis	or	psoriasis	in	combination	with	PsA,	DMARDS	
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show	 reduced	 quality	 of	 life51-54,	 other	 studies	 show	 no	 difference	 between	 IBD	 patients	 and	 the	









patients	often	use	medication,	among	which	the	expensive	biologicals,	 for	 long	periods	of	 time.	 In	
addition,	 a	 lot	 of	 IBD	 patients	 need	 surgery	 or	 even	multiple	 surgeries.53	 It	 seems	 apparent	 that	





have	 their	own	 treatment	options.	Treatment	 for	 IBD	also	 follows	a	 step-up	strategy.	First	 step	of	
treatment	is	5-aminosalicylic	acid	(mesalazine	or	sulfalazine)	or	steroids.	The	following	steps	include	







IBD	patients	with	axial	or	peripheral	 involvement.	As	with	PsA,	 first	 choice	of	 treatment	would	be	
NSAIDs.	However,	 long-term	treatment	of	NSAIDs	should	be	avoided	 in	patients	with	 IBD	as	 it	can	
increase	the	risk	for	relapse	of	IBD.	Evidence	suggests	that	selective	COX-2	inhibitors	may	be	a	better	
option	 as	 they	 do	 not	 seem	 to	 cause	 relapse	 of	 IBD.50,63,64	 For	 patients	 with	 axial	 involvement,	
biologicals	(anti-TNFα)	are	the	first	choice	of	treatment	after	failure	of	or	intolerance	for	NSAIDs.	A	lot	
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Another	way	 to	aid	early	 recognition,	 is	 screening.	The	concept	of	 screening	 is	 to	 identify	possible	
disease	 in	patients	without	 signs	or	 symptoms.	 This	 has	been	widely	 implemented	 in	 for	 example	





















suffered	 from	 any	 kind	 of	 MSC.	 All	 eligible	 patients	 willing	 to	 participate,	 completed	 a	 set	 of	
questionnaires	and	were	subsequently	invited	for	clinical	evaluation	by	a	trained	research	assistant.	










and	 invite	 them	 to	 participate.	 In	 addition,	 patients	 were	 recruited	 via	 the	 Dutch	 patients’	
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In	 Chapter	 2	 we	 describe	 the	 results	 of	 a	 cross-sectional	 study	 estimating	 the	 prevalence	 of	
musculoskeletal	 complaints	 and	 PsA	 in	 primary	 care	 psoriasis	 patients.	 Chapter	 3	 focuses	 on	 an	
important	but	scarcely	studied	part	of	PsA,	namely	enthesitis.	 In	this	study	we	aimed	to	assess	the	
frequency	 of	 clinically	 relevant	 ultrasound	 inflammation	 at	 the	 entheses	 of	 primary	 care	 psoriasis	
patients.		
Chapter	4	focuses	on	the	prevalence	of	the	various	manifestations	of	SpA	in	patients	suffering	from	







awareness	 and	 screening.	 Chapter	 6	 describes	 the	 current	 practice	 of	 Dutch	 GPs	 with	 regard	 to	
inflammatory	musculoskeletal	complaints.	With	this	survey	we	aimed	to	gain	insight	in	the	knowledge	
and	awareness	of	GPs	with	regard	to	SpA	and	patients	with	psoriasis	or	IBD	at	risk	for	SpA.	Besides	the	
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Prevalence and Burden of Spondyloarthritis 
in Patients at Risk

Chapter 2.



















Methods.	 We	 conducted	 a	 cross-sectional	 study	 in	 adult	 primary	 care	 patients	 with	 psoriasis.		
Responding	patients	reporting	pain	in	joints,	entheses	or	lower	back	were	checked	on	eligibility	by	a	
telephone	interview	and	invited	for	clinical	evaluation.	During	clinical	evaluation	skin,	nails,	joints	and	




Results.	 2564	 psoriasis	 patients	 from	 97	 GPs	 were	 invited.	 Of	 the	 1673	 responders	 (65.2%),	 841	
(50.3%)	 were	 willing	 to	 participate.	 823	 (32.1%)	 patients	 reported	 suffering	 from	 MSC	 of	 which	












is	 consulted.1	 PsA	 is	well	 treatable	 and	an	 increasing	number	of	 studies	 show	 that	 early	diagnosis	
improves	the	outcome	substantially.2-6	In	most	cases	PsA	is	preceded	by	psoriasis,	which	affects	2-3%	
of	 the	 Western	 population.7-9	 Estimates	 of	 the	 prevalence	 of	 PsA	 among	 psoriasis	 patients	 are	






The	 primary	 objective	 of	 this	 study	 was	 to	 give	 an	 estimate	 of	 the	 prevalence	 of	 PsA	 including	







participating	 GPs	 (n=97;	 36%)	 selected	 their	 psoriasis	 patients	 aged	 18	 years	 and	 over	 from	 their	
databases	using	ICPC	code	S91	(International	Classification	of	Primary	Care	code	for	psoriasis).14	In	the	
Netherlands,	the	ICPC	is	the	standard	for	coding	and	classification	of	signs	and	symptoms	in	general	
practice.	 The	 identified	 psoriasis	 patients	 received	 an	 invitation	 from	 their	 GP	 asking	 them	 to	
participate.	 Patients	were	asked	 to	 return	 the	 reply	 slip,	which	 contained	 two	questions.	 The	 first	
question	was	if	they	did	or	did	not	suffer	from	regular	joint	complaints,	back	complaints	or	tendon	
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Questionnaires.	Patients	were	asked	 to	complete	 three	questionnaires	 related	 to	 their	 complaints.	
Indication	 of	 inflammatory	 back	 pain	 was	 assessed	 by	 the	 ASAS-IBP	 (ASAS	 questionnaire	 on	
Inflammatory	Back	Pain)15,	which	consists	of	five	yes-no	questions.	To	assess	the	presence	of	other	
MSC	 the	 PEST	 (Psoriasis	 Epidemiology	 Screening	 Tool)16	 and	 the	 EARP	 (Early	 Psoriatic	 Arthritis	









and	 the	degree	of	 severity	of	 erythema,	 induration	 and	 scaling	weighted	by	body	 area.	 The	 score	
ranges	 between	 0	 and	 72	 and	 a	 score	 above	 10	 is	 considered	 to	 represent	 moderate	 to	 severe	




MASES	 (Maastricht	Ankylosing	 Spondylitis	 Enthesitis	 Score)21.	 The	 LEI	 consists	 of	 6	 entheseal	 sites	














Patients	 were	 advised	 to	 consult	 a	 rheumatologist	 if	 there	 were	 indications	 of	 underlying	
rheumatological	 disease.	 Referral	 criteria	 were	 set	 up	 and	 these	 included	 an	 evident	 history	 of	
dactylitis	or	arthritis	as	well	as	current	peripheral	or	axial	manifestations.	Peripheral	manifestations	
were	 defined	 as	 arthritis	 in	 one	 or	 more	 joints	 upon	 physical	 examination	 or	 enthesitis	 at	 US	
examination.	Possible	axial	manifestation	was	defined	as	low	back	pain	for	more	than	12	consecutive	





The	 diagnosis	 of	 PsA	was	 based	 on	 the	 CASPAR	 criteria,	 where	 patients	must	 have	 inflammatory	
articular	disease	in	the	joints,	spine	or	entheses.25	On	top	of	this,	at	least	3	out	of	the	following	6	points	
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same	assumption	as	 in	 the	 first	 scenario.	 The	 third	 scenario	equals	 the	 second	with	 regard	 to	 the	

























































comprised	 the	 841	 patients	 that	 were	 interested	 in	 participating,	 of	 which	 during	 a	 telephone	
interview	 659	 patients	 reported	 regular	 suffering	 from	MSC.	 Of	 these	 659	 patients,	 581	 (88.2%)	
reported	 regular	 spells	 of	 joint	 complaints,	 recurrent	 tendon	 complaints	 were	 reported	 by	 332	
patients	(50.4%)	and	low	back	pain	was	reported	by	487	patients	(73.9%).		In	total	823	of	2564	patients	
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psoriasis	 duration	 was	 21.0±16.3	 years,	 with	 74%	 of	 the	 psoriasis	 diagnoses	 confirmed	 by	 a	
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Mean Age, years (±SD) 47.4 (10.7) 58.0 (12.3) 56.1 (14.4) 55.9 (14.0)
Male sex, n (%) 8 (47.1) 17 (47.2) 21 (41.2) 216 (51.4)
Body Mass Index, mean (±SD) 27.9 (6.2) 30.0 (4.1) 28.2 (8.3) 27.8 (4.8)
Median Psoriasis Symptom Duration, years 
(IQR)
15 (4-30) 20 (11-37) 20 (12-33) 15 (8-30)
Psoriasis Diagnosis by Dermatologist, n (%) 13 (76.5) 31 (86.1) 42 (82.4) 302 (71.9)
Nail psoriasis, n (%) 5 (29.4) 2 (5.6) 10 (19.6) 64 (15.2)
PASI, median (IQR) 3 (1.3-4) 3.1 (1.7-4.4) 1 (0-3) 2.2 (1-4)
Median MSC Symptom Duration, years (IQR)
                                                                              Joints 12.5 (2-23) 10 (5-25) 12 (8-20) 8 (4-14)
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LEI, median (IQR) 0 (0-1) 1 (1-2) 0 (0-1) 0 (0-0)
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PsA=Psoriatic Arthritis, PASI=Psoriasis Area&Severity Index, MSC=musculoskeletal complaints, LEI=Leeds 
Enthesitis Index, MASES= Maastricht Ankylosing Spondylitis Enthesitis Score
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suffering	 from	MSC	 was	 9.8%	 (81	 PsA	 cases	 in	 823	 patients	 with	MSC).	 We	 assumed	 that	 these	




























Previous	 literature	 about	 the	 prevalence	 of	 PsA	 in	 primary	 care	 is	 scarce.12,13	 A	 higher	
prevalence	of	8.6%	(95%	CI	7.7-9.5%)	was	observed	by	Ogdie	et	al.13	One	of	the	explanations	for	this	
difference	 could	 be	 that	 they	 based	 the	 diagnosis	 of	 PsA	 on	medical	 codes	 in	 a	 population-based	
medical	records	database	rather	than	clinical	examination.	An	even	higher	prevalence	was	reported	
by	 Ibrahim	 et	 al	 (13.8%	 (95%CI	 7.1-24.1%)),	 but	 this	 study	 had	 substantial	 non-response.12	 The	
prevalence	would	 reduce	 towards	 1.9%	 if	 all	 initial	 patients	would	 be	 taken	 into	 account	 and	 no	
additional	cases	would	be	found	in	the	non-responders.	More	data	is	available	from	secondary	care,	
where	PsA	prevalence	figures	range	from	6%	to	42%	among	psoriasis	patients.10,29	This	wide	spread	is	
likely	 to	 be	 caused	 by	 the	 use	 of	many	 different	 criteria	 sets,	 self-reported	 patient	 diagnosis	 and	
diagnosis	by	the	dermatologist.		
Defining	 PsA	 has	 proven	 to	 be	 challenging	 due	 to	 its	 clinical	 heterogeneity.	 In	 2006,	 new	
classification	criteria	were	established,	the	CASPAR	criteria.25	Besides	peripheral	synovitis	and	axial	
disease,	 entheseal	 involvement	 was	 characterized	 as	 inflammatory	 articular	 disease.	 Enthesitis	 is	
















are	 not	 able	 to	 recruit	 patients	 yourself.	 Secondly,	 our	 study	 provides	 prevalence	 estimates	 for	
primary	care	and	as	mentioned	before	only	two	studies	reported	about	the	prevalence	in	a	primary	
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prevalence.32	 For	 example,	 1%	of	 the	Asian	 psoriasis	 patients	 is	 affected	 by	 PsA	 versus	 10-42%	 in	
Europe	and	North-America.33	 In	our	 study	population	about	98%	were	 from	Caucasian	origin.	 This	
should	be	taken	into	account	when	interpreting	the	results.	Self-selection	related	to	symptoms	might	
have	been	an	 issue	as	we	observe	 that	 the	mean	age	of	 the	 responders	was	55.8±13.9	 years	 and	
people	of	older	age	tend	to	have	more	joint	complaints.	The	ideal	population	would	be	younger,	as	
we	know	that	 the	peak	 incidence	of	PsA	 is	between	30	and	50	years	of	age.	 It	 could	 therefore	be	
possible	that	we	missed	some	cases	among	the	younger	patients	who	did	not	participate.	In	addition,	
we	 only	 invited	 patients	with	 regular	 spells	 of	MSC.	 This	might	 have	 left	 us	with	missed	 cases	 as	
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Adding Ultrasound to Clinical Examination reduced 
Frequency of Enthesitis in Primary Care Psoriasis 
Patients with Musculoskeletal Complaints























contained	positive	power	Doppler	signal	or	 in	case	of	 the	plantar	aponeurosis	 increased	thickness.	
Structural	 changes	 entailed	 calcifications,	 enthesophytes,	 increased	 thickness,	 hypoechogeneicity	
indicating	irregular	fiber	structure	and	erosions.	Clinically,	an	enthesis	was	scored	positive	by	a	tender	
enthesis	 at	 clinical	 examination,	 reported	 pain	 in	 the	 history	 or	 self-reported	 pain	 in	 the	
questionnaires.		
	
Results.	 Of	 542	 primary	 care	 psoriasis	 patient,	 111	 patients	 had	 tender	 entheses	 and/or	 arthritis.	
These	 patients	 were	 both	 clinically	 and	 ultrasonographically	 evaluated.	 Active	 ultrasound	
inflammation	accompanied	with	pain	or	tenderness	at	the	enthesis	was	found	in	36%	of	the	patients	
(n=40).	Most	common	were	inflammation	at	the	knee	(n=11)	and	at	the	plantar	aponeurosis	(n=10).	
Structural	 changes	 were	 observed	 in	 95%	 of	 the	 psoriasis	 patients	 independent	 of	 their	 clinical	
manifestation.	
	





Enthesitis	 is	an	 important	domain	 in	psoriatic	arthritis	 (PsA).	Since	 the	 introduction	of	 the	CASPAR	
classification	 criteria	 for	 PsA	 in	 2006,	 psoriasis	 patients	 can	 classify	 as	 PsA	with	 only	 enthesitis	 as	
inflammatory	articular	involvement.1	Increasing	attention	is	paid	to	its	assessment2,	3,	but	up	to	now	
no	 consensus	 has	 been	 achieved	 on	 its	 measurements	 in	 the	 diagnostic	 setting.	 In	 both	 the	
classification	criteria	for	PsA	and	spondyloarthritis	(SpA),	enthesitis	is	included.	The	CASPAR	criteria	
suggest	that	the	doctor	diagnoses	enthesitis	as	he	sees	fit.	The	ASAS	criteria	for	peripheral	SpA	include	





response.7	 Clinical	 assessment	 of	 the	 entheses	 is	 difficult	 as	 inflammation	 is	 often	 not	 visible	 or	
palpable.	In	addition,	it	may	be	difficult	to	anatomically	locate	the	enthesis	if	it	lies	deep	within	the	
surrounding	tissue.8	The	location	of	several	entheseal	sites	overlaps	with	those	of	the	tender	points	
of	 fibromyalgia.9	 Furthermore,	 the	 presence	 of	 a	 tender	 enthesis	 is	 not	 necessarily	 indicative	 for	
underlying	 inflammatory	 disease	 as	 it	 could	 be	 related	 to	 overuse,	metabolic	 disease	 or	 ageing.10	
These	challenges	could	lead	to	clinically	false-positive	patients.		
To	resolve	the	difficulties	regarding	clinical	assessment	of	the	entheses,	inflammatory	characteristics	
at	 the	 enthesis	 can	 be	 visualized	 by	 ultrasound.11	 Especially	 the	 use	 of	 the	 power	 Doppler	mode	
improves	the	assessment	of	inflammation	at	the	entheses.12,	13	New	data	about	ultrasound	enthesitis	
emerged	in	patients	with	psoriasis,	PsA	and	healthy	controls.14-16	So	far,	studies	evaluated	enthesitis	
in	 patients	 with	 psoriasis	 who	 were	 referred	 from	 the	 dermatologist.16-20	 A	 significant	 higher	
prevalence	of	both	grayscale	 (GS)	 and	power	Doppler	 (PD)	ultrasound	enthesopathy	was	 found	 in	
patients	with	psoriasis	than	in	controls	(patients	with	dermatological	diseases	other	than	psoriasis).16-
18	In	patients	with	PsA	the	severity	of	ultrasound	abnormalities	was	even	higher	than	in	patients	with	
psoriasis.20	 Ultrasound	 abnormalities	 at	 the	 entheses	 were	 present	 in	 both	 symptomatic	 (true-
positive)	 and	asymptomatic	 (false-positive	or	 subclinical	 disease)	psoriasis	 patients	which	 suggests	
single	application	of	ultrasound	is	not	sufficient	to	detect	clinically	relevant	entheseal	inflammation.19,	
21	
Little	 data	 is	 available	 on	 the	 presence	 of	 PsA	 in	 primary	 care	 psoriasis	 patients.22,	 23	 In	 several	
countries	psoriasis	patients	are	treated	by	their	general	practitioner	and	this	might	mean	that	cases	
of	PsA	are	missed.	In	addition,	these	studies	did	not	include	ultrasound	to	assess	inflammation	at	the	
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information	 in	 primary	 care	 psoriasis	 patients	 who	 had	 at	 least	 one	 tender	 enthesis	 at	 clinical	









nurse.	 Patients	 were	 not	 recruited	 consecutively.	 Data	 collection	 included	 a	 detailed	 clinical	























system	 the	 following	 elemental	 lesions	 of	 enthesitis	 were	 evaluated	 at	 each	 site:	 calcifications,	
bursitis,	erosions,	PD	signal	 in	bursa	or	enthesis	 full	 tendon	(cortical	bone	profile,	 intratendon	and	
paratendon	on	the	enthesis	insertion)	and	thickness	and	structure.25	Ultrasound	abnormalities	were	
divided	 into	 ‘active	 inflammation’	 and	 ‘structural	 change’	 parameters.	 Active	 inflammatory	
components	on	ultrasound	included	the	presence	of	PD	signal	(<2mm	of	the	bony	cortex)15	or	in	case	




Patients	 completed	online	 self-reported	questionnaires	 including	 the	EARP27	 and	PEST28.	 From	 the	
EARP	questionnaire	we	used	the	question	regarding	the	Achilles	tendon.	From	the	PEST	questionnaire	





In	 this	 study	 we	 combined	 data	 from	 ultrasound	 and	 clinical	 examination,	 and	 patient-reported	
questionnaires	 to	 define	 active	 inflammation	 at	 the	 enthesis.	 We	 defined	 enthesitis	 as	 active	
inflammation	 on	 ultrasound	 (presence	 of	 PD	 signal	 and/or	 increased	 thickness	 of	 the	 plantar	
aponeurosis)	 in	combination	with	at	 least	one	clinical	 feature	at	the	same	enthesis:	 i)	tender	point	
LEI/MASES,	ii)	self-reported	pain	at	the	elbow,	knee,	Achilles	tendon	and	heel	from	the	EARP	or	PEST	




To	 determine	 differences	 in	 baseline	 characteristics	 and	 ultrasound	 findings	 between	 patients	
suspected	for	enthesitis	and	patients	suspected	for	arthritis	we	used	descriptive	statistics.	Depending	
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In	 total,	 111	 patients	 of	 the	 total	 study	 population	with	 psoriasis	 (n=524)	who	 reported	 regularly	
musculoskeletal	 complaints	 were	 evaluated	 by	 ultrasound.	 Of	 these	 patients,	 88	 patients	 were	
referred	for	ultrasound	because	they	had	at	least	one	tender	enthesis	on	the	LEI/MASES.	The	other	
23	patients	were	referred	for	suspected	arthritis	and	also	underwent	an	evaluation	of	the	entheses	by	
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In	 106	 (95%)	 patients	 (n=111)	we	detected	one	or	more	ultrasound	 abnormalities	 at	 the	 enthesis	
[Table	2].	There	was	no	difference	in	ultrasound	findings	between	patients	suspected	for	enthesitis	
and	patients	suspected	for	arthritis.		






















































Table 1 Baseline characteristics of primary care psoriasis patients (n=111)
Suspected for enthesitis 
(n=88)
Suspected for arthritis 
(n=23)
p-value
Women (%) 57 39 0.130
Age, years (mean, sd) 54 (13) 54 (14) 0.936
LEI (median, IQR) 2 (1-4) 0 (0-1) <0.001
MASES (median, IQR) 2 (0-4) 0 (0-1) <0.001
MASEI (median, IQR) 7 (5-12) 10 (5-13) 0.302
Power Doppler positive, n (%) 0.626
- 1 enthesis 14 (16) 2 (9)
- 2 entheses 12 (14) 3 (13)
- 3 entheses 3 (3) 1 (4)
LEI = Leeds Enthesitis Index (range: 0-6); MASES = Maastricht Ankylosing Spondylitis Enthesis Score (range: 
0-13); MASEI = Madrid Sonographic Enthesis Index (range: 0-136); sd = standard deviation; IQR = interquartile 
range
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Table 2 Ultrasound abnormalities at the enthesis using the MASEI score (n=111)
Insertion PD signal Structure Thickness Bursitis Erosion Calcification
Lateral epicondyle tendon (elbow)* 21 (19) 19 (17) 51 (46) 35 (32) 47 (42)
Triceps tendon* 0 25 (23) 18 (16) 9 (8) 26 (23)
Quadriceps tendon* 13 (12) 12 (11) 53 (48) 3 (3) 66 (59)
Proximal patella tendon* 2 (2) 4 (4) 29 (26) 2 (1) 15 (14)
Distal patella tendon* 9 (8) 3 (3) 77 (69) 1 (1) 3 (3) 23 (21)
Achilles tendon* 4 (4) 1 (1) 12 (11) 0 1 (1) 70 (63)
Plantar aponeurosis * † 1 (1) 20 (18) 0 20 (18)


















Figure	 1	 shows	 the	 distribution	 of	 the	 ultrasound	 findings,	 both	 structural	 changes	 and	 active	
inflammation	combined	with	the	clinical	findings	at	each	entheseal	site.	
Five	 patients	 had	 a	 painful	 enthesis	 clinically	without	 having	 any	 ultrasound	 abnormalities.	 These	








In	 36%	of	 the	primary	 care	psoriasis	 patients	who	had	 tenderness	 at	 one	or	more	entheseal	 sites	
(n=111)	enthesitis	was	present,	defined	as	concurrent	presence	of	ultrasound	inflammatory	changes	
and	 clinical	 symptoms.	 Ultrasound	 assessment	 included	 five	 elemental	 lesions:	 the	 presence	 of	
calcifications,	 erosions,	 increased	 thickness,	 changes	 in	 fiber	 structure,	 and	positive	PD	 signal.	We	
indicated	the	first	4	lesions	as	‘structural	changes’	of	the	enthesis	which	were	present	in	95%	of	the	






n=10)	 we	 found	 ultrasound	 inflammatory	 components,	 but	 these	 were	 not	 confirmed	 by	 clinical	
information.	 This	 could	 be	 related	 to	 subclinical	 disease,	 which	 could	 be	 predictive	 for	 the	
development	of	PsA	in	patients	with	psoriasis.21,	29-31		
Considerable	advances	have	been	made	in	the	use	of	ultrasound	to	evaluate	entheses.	Nevertheless,	
context	 of	 clinical	 information	 remains	 needed	 to	 differentiate	 between	 active	 inflammation	 and	
other	manifestations	of	enthesopathy.10	By	adding	ultrasound	to	the	clinical	evaluation	of	entheses	
we	were	able	to	visualize	the	presence	of	active	inflammatory	involvement	of	the	enthesis.	This	could	
help	 to	 differentiate	 patients	with	 non-inflammatory	 entheseal	 pain	 from	patients	with	 entheseal	
involvement	related	to	inflammation,	helping	physicians	to	make	informed	decisions	about	whom	to	
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n=10)	 we	 found	 ultrasound	 inflammatory	 components,	 but	 these	 were	 not	 confirmed	 by	 clinical	
information.	 This	 could	 be	 related	 to	 subclinical	 disease,	 which	 could	 be	 predictive	 for	 the	
development	of	PsA	in	patients	with	psoriasis.21,	29-31		
Considerable	advances	have	been	made	in	the	use	of	ultrasound	to	evaluate	entheses.	Nevertheless,	
context	 of	 clinical	 information	 remains	 needed	 to	 differentiate	 between	 active	 inflammation	 and	
other	manifestations	of	enthesopathy.10	By	adding	ultrasound	to	the	clinical	evaluation	of	entheses	
we	were	able	to	visualize	the	presence	of	active	inflammatory	involvement	of	the	enthesis.	This	could	
help	 to	 differentiate	 patients	with	 non-inflammatory	 entheseal	 pain	 from	patients	with	 entheseal	
involvement	related	to	inflammation,	helping	physicians	to	make	informed	decisions	about	whom	to	
treat	 with	 anti-inflammatory	 drugs.	 First-line	 treatment	 recommendations	 for	 enthesitis	 in	 PsA	
Table 3 Ultrasound and clinical findings per entheseal site (n=111)








Lateral epicondyle tendon (elbow) 21 (19) 62 (56) 58 (52) 54 (49)
Triceps tendon 0 49 (44) † 54 (49)
Quadriceps tendon 13 (12) 68 (61) 55 (50)* 79 (71)
Proximal patella tendon 2 (2) 37 (33)
Distal patella tendon 9 (8) 74 (67)
Achilles tendon 4 (4) 68 (61) 32 (29) 19 (17)
Plantar aponeurosis 20 (18) 16 (14) † 61 (55)
US = ultrasound; † = not included in LEI/MASES; * = medial epicondyle femur


















Figure	 1	 shows	 the	 distribution	 of	 the	 ultrasound	 findings,	 both	 structural	 changes	 and	 active	
inflammation	combined	with	the	clinical	findings	at	each	entheseal	site.	
Five	 patients	 had	 a	 painful	 enthesis	 clinically	without	 having	 any	 ultrasound	 abnormalities.	 These	
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aponeurosis	 insertion	 on	 MRI	 appearances.34	 However,	 thickening	 could	 also	 be	 the	 result	 of	 a	
disorganized	repair	process	(scar	tissue)	in	which	no	inflammation	is	present	anymore.		
There	are	several	strengths	and	weaknesses	to	discuss	when	interpreting	the	results	of	our	study.	At	
first,	 for	 practical	 reasons	 we	 choose	 to	 apply	 ultrasound,	 rather	 than	MRI.	 Ultrasound	was	 easy	
accessible,	we	could	apply	it	to	different	locations	at	once	and	there	were	no	safety	issues.	It	has	the	
disadvantage	 that	 it	 is	 reader	 dependable,	 which	 was	 solved	 by	 one	 examiner	 for	 all	 patients.	
However,	ultrasound	cannot	depict	bone	edema	which	is	also	indicative	for	inflammatory	changes	like	
MRI	 does.	MRI	 is	 capable	 of	 detecting	 soft	 tissue	 changes	 associated	with	 surrounding	 soft	 tissue	







facilitates	 collapse	 of	 the	microvessels.	 Thirdly,	 due	 to	 the	 aim	 of	 our	 initial	 study,	 which	was	 to	
estimate	the	prevalence	of	PsA	in	primary	care	psoriasis	patients,	we	did	not	include	control	patients.	
However,	 there	 is	a	 substantial	body	of	evidence	 that	 shows	 the	usefulness	of	 the	MASEI	 score	 in	
differentiating	 patients	 with	 PsA/SpA	 from	 healthy	 controls20,	 37,	 especially	 if	 using	 inflammatory	
changes	(PD	signal)	rather	than	structural	changes.21	This	stresses	our	choice	to	use	a	positive	PD	signal	
at	 the	enthesis	as	an	 indication	for	active	ultrasound	enthesitis.	A	strength	of	our	study	 is	 that	we	
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The Prevalence and Incidence of Axial and Peripheral 
Spondyloarthritis in Inflammatory Bowel Disease: 











population.	 Various	 extraintestinal	 manifestations	 occur,	 among	 which	 rheumatic	 manifestations,	
grouped	together	under	the	name	spondyloarthritis.	The	objective	of	the	systematic	review	and	meta-
analysis	was	 to	give	a	 systematic	overview	of	 the	prevalence	and	 incidence	of	 spondyloarthritis	 in	
patients	with	inflammatory	bowel	disease.		
	
Methods.	 We	 systematically	 searched	 Embase,	 Pubmed,	 OvidSP,	 Scopus	 and	 Web-of-science	
databases	from	inception	to	August	2016.	All	articles	that	addressed	the	prevalence	or	incidence	of	


















tract,	 which	 encompasses	 both	 Crohn’s	 disease	 (CD)	 and	 ulcerative	 colitis	 (UC).	 IBD	 can	 be	
accompanied	by	a	number	of	extra-intestinal	manifestations	(EIM)	in	multiple	organ	systems,	among	







IBD	activity,	 usually	 affects	 five	 joints	or	 less	 and	 tends	 to	be	 self-limiting.	 Type	2	 arthritis	 usually	
affects	more	 than	 five	 joints	 and	does	not	 correlate	with	 IBD	activity.3	Although	 this	 distinction	 is	
widely	used	 in	gastroenterology	practice,	 it	 is	not	often	used	by	rheumatologists.	Rheumatologists	
tend	 to	 follow	 the	 recently	 developed	 ASAs	 criteria,	 which	make	 a	 distinction	 between	 axial	 and	
peripheral	manifestations.9,10	Both	axial	and	peripheral	manifestations	can	occur	in	patients	with	IBD.	
With	regard	to	the	axial	manifestations	of	SpA,	the	main	symptom	is	chronic	low	back	pain	induced	by	
inflammation	of	 the	sacroiliac	 joints,	 the	so-called	sacroiliitis	 (SI).	Ankylosing	spondylitis	 (AS)	 is	 the	
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Data	was	extracted	by	one	 investigator	 (MK)	according	 to	a	pre-defined	data	 form.	 	The	 following	
information	 was	 extracted:	 setting	 (population	 based,	 secondary	 care,	 tertiary	 care	 (university	
hospital)),	 type	 of	 study,	 study	 population,	 number	 of	 IBD	 patients	 participating,	 mean	 age	 and	
percentage	women	of	 IBD	patients,	criteria	 for	establishment	of	 IBD,	disease	duration	of	 IBD,	case	







about	 representativeness	 of	 the	 sample	 for	 the	 target	 population,	 appropriate	 recruitment	 of	 the	
study	 participants,	 adequate	 sample	 size	 calculation	 and	 if	 the	 data	 analysis	 was	 conducted	with	
sufficient	coverage	of	the	identified	sample.	With	regard	to	case	ascertainment,	we	included	questions	
about	 whether	 objective,	 standard	 criteria	 were	 used	 for	 the	 establishment	 of	 a	 case	 and	 if	 the	






peripheral	 manifestation	 arthritis	 in	 patients	 with	 CD	 and	 UC.	 For	 the	 peripheral	 manifestations	
enthesitis	 and	 dactylitis	 too	 few	 studies	 were	 available	 for	 pooling,	 so	 these	 were	 described	
narratively.	
Meta-analysis	was	 performed	using	 the	 ‘metaprop’	 command	 in	 Stata	 13,	 using	 a	 random	effects	





The	 search	 resulted	 in	 4533	 publications	 (Figure	 1).	 After	 removing	 duplicates	 2780	 publications	
remained	and	were	screened	on	title	and	abstract.	Eventually	658	publications	were	found	eligible	for	
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assessment	tool	with	instructions	how	 e	applied	the	tool	can	be	found	in supplemental	fi e	S2.	All	
pa ers	were	discussed	between	MK	and	AW	or	JL and	disagreements	were	 solved	by	consensu .		
	
Pooling	of data	
A	met -an lysis	was	p rform d	for	the	prevalence	of	the	axi l	manifestations	AS	and	SI and	for	the	
peripheral	 manifestation	 arthritis	 n	 patients	 with	 CD	 and	 UC.	 For	 the	 peripheral	 manifestations	
enthesitis	 and	 actylitis	 too	 few	 studies	 were	 av il ble	 for	 pooling,	 so	 thes 	 were	 described	
narr tively.	
Meta-an lysis	was	 performed	using	 the	 ‘metaprop’	 com and	 in	 Stata	 13,	 using	 a	 random	eff cts	
model.13	 I2 was	 used	 to	 cal ulate	 the	 between-study	 heterogen ity.	 Meta-an lysis	 according	 to	




The	 search	 resulted	 in	 4533	 publications	 (Figure	 1).	 After	 removing	 duplicates	 2780	 publications	
remained	and	were	screen d	on	title	and	abstract.	Eventually	658	publications	were	found	eligible	for	
full-text	 revi w,	after whic 	71	publications	were	 i clude .	Thes 	71	publications	 reported	on	 the	
prevalence	of the	different	axi l	 nd	peripheral	joint	manifestations	of SpA	in either	CD	or	UC.	Sev n	
studies	did	not	specify	the	type	of inflam atory	bowel	disease	and	are	described	as	unspecified	IBD.	
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S2.	 In	 table	2	 the	different	 items	of	 the	quality	 list	are	 shown	with	 the	percentage	of	 studies	 that	
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years.	Studies	were	performed	 in	different	settings,	resulting	 in	higher	prevalences	of	SI	 in	tertiary	














Patients	 with	 CD	 had	 a	 slightly	 higher	 prevalence	 of	 AS	 than	 patients	 with	 UC;	 4%	 (95%CI	 3-5%)	
compared	to	2%	(95%CI	1-3%).	
To	look	into	potential	explanations	for	the	heterogeneity,	the	prevalence	estimates	for	AS	are	shown	





age	 groups	 (3%,95%CI	 2/1%-5/%	 respectively).	 Study	 characteristics	 like	 setting,	 outcome	
measurement	and	case	ascertainment	seemed	to	influence	the	reported	prevalences.	The	differences	
are	 small,	 with	 slightly	 higher	 prevalences	 in	 tertiary	 care	 setting,	 diagnoses	 based	 on	 clinical	
evaluation	and	the	use	of	the	recommended	(modified)	New	York	criteria	to	diagnose	AS.	
	
Table 2 Risk of Bias Assessment
% Positive
Was the sample representative of the target population? 63.4
Were study participants recruited in an appropriate way? 90.1
Was the sample size adequate? 0
Was the data analysis conducted with sufficient coverage of the identified sample? 59.2
Were objective, standard criteria used for the measurement of the condition? 56.3
Was the condition measured reliably? 46.5
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The	pooled	prevalence	of	 peripheral	 arthritis	 (79	 estimates)	was	 13%	 (95%CI	 12-15%)	with	 a	 high	
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peripheral	 arthritis	 was	 higher	 in	 patients	 with	 CD	 than	 in	 patients	 with	 UC.	 This	 difference	 in	
prevalence	estimates	has	been	described	before.2,4,83	For	the	prevalence	of	enthesitis	and	dactylitis	
fewer	estimates	were	available.	The	prevalence	of	enthesitis	had	a	wide	range	from	1%	(95%CI	0-6%)	








studies	will	underestimate	 the	prevalence	of	AS	 in	 IBD.	The	same	applies	 for	 studies	performed	 in	
secondary	care,	which	seem	to	estimate	a	lower	prevalence	of	the	different	SpA	manifestations	than	
studies	in	tertiary	care.	This	could	imply	that	tertiary	care	centers	are	more	focused	on	joined	care	
between	 gastroenterologists	 and	 rheumatologists	 to	 enhance	 recognition	 of	 SpA	 in	 IBD	 patients.	
Geographic	 area	 also	 contributes	 to	 the	 heterogeneity	 and	 prevalences	 for	 axial	 manifestations	
(SI&AS)	 are	 highest	 in	 Europe	 and	 North-America.	 This	 is	 in	 line	 with	 the	 estimates	 for	 SpA	 in	





their	 participants	 adequately,	 but	 merely	 65%	 selected	 a	 sample	 representative	 of	 the	 target	
population.	The	results	of	these	studies	therefore	have	poor	external	validity.	Even	though	the	quality	
of	the	included	studies	differed	widely,	we	chose	not	to	pool	on	the	quality	in	the	meta-analysis	as	it	











certain	 studies.	 	 Secondly,	 only	 one	 author	 performed	 the	 screening	 of	 the	 papers	 and	 the	 data	
extraction.	Ideally,	this	would	have	been	done	independently	by	two	authors.	However,	we	discussed	
beforehand	with	 all	 authors	which	 papers	 to	 include	 and	which	 not.	 In	 addition,	 the	 author	who	
performed	the	screening	was	very	liberal	and	in	case	of	any	doubt,	the	paper	was	discussed	with	one	
of	 the	 other	 authors	 until	 consensus	 was	 reached.	 Thirdly,	 we	 used	 a	 risk	 of	 bias	 tool	 especially	
developed	 for	 prevalence	 studies,	 but	 left	 some	 items	 out	 as	 these	 did	 not	 seem	 to	 apply	 to	 our	
selected	studies.	We	left	out	items	about	the	description	of	study	subjects	and	setting	as	we	gathered	
this	 information	 in	 the	 data-extraction.	 Items	 about	 the	 definition	 of	 subgroups	 and	 differences	
between	subgroups	were	also	left	out,	as	we	only	looked	at	prevalence	in	the	complete	groups.	As	we	
do	not	take	the	quality	into	account	when	pooling	the	results,	we	do	not	think	leaving	out	these	items	

























peripheral	 arthritis	 was	 higher	 in	 patients	 with	 CD	 than	 in	 patients	 with	 UC.	 This	 difference	 in	
prevalence	estimates	has	been	described	before.2,4,83	For	the	prevalence	of	enthesitis	and	dactylitis	
fewer	estimates	were	available.	The	prevalence	of	enthesitis	had	a	wide	range	from	1%	(95%CI	0-6%)	








studies	will	underestimate	 the	prevalence	of	AS	 in	 IBD.	The	same	applies	 for	 studies	performed	 in	
secondary	care,	which	seem	to	estimate	a	lower	prevalence	of	the	different	SpA	manifestations	than	
studies	in	tertiary	care.	This	could	imply	that	tertiary	care	centers	are	more	focused	on	joined	care	
between	 gastroenterologists	 and	 rheumatologists	 to	 enhance	 recognition	 of	 SpA	 in	 IBD	 patients.	
Geographic	 area	 also	 contributes	 to	 the	 heterogeneity	 and	 prevalences	 for	 axial	 manifestations	
(SI&AS)	 are	 highest	 in	 Europe	 and	 North-America.	 This	 is	 in	 line	 with	 the	 estimates	 for	 SpA	 in	
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Gastroenterologists,	 especially	 in	 secondary	 care,	 should	 pay	 attention	 to	 their	 IBD	 patients	 with	
musculoskeletal	complaints	since	they	are	common	and	might	cause	significant	impact	on	quality	of	
life,	 even	 in	 the	 absence	 of	 inflammation.8	 IBD	 patients	 are	 prone	 to	 develop	 SpA	 and	 should	 be	
recognized	early	as	the	benefits	of	early	treatment	are	well	established.90,91	
	 In	 conclusion,	 we	 calculated	 pooled	 prevalences	 for	 SI	 (10%),	 its	 subtype	 AS(3%)	 and	
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Risk of Bias Assessment Instructions
YES NO
1. Was the sample 
representative of the 
target population?
The sample was representative of the 
target po ulation.  Selected p tients are 
representative of an IBD population. No pre-
selection took place in selecting the patients 
based on for example work.
The center from which the IBD patients 
were recruited should me mentioned
Sample was not 
representative.
2. Were study participants 
recruited in an appropriate 
way?
Patients were recruited from an appropriate 
source and were “randomly” invited for the 
study (all patients OR consecutive patients 
OR random patients)
Patients were not recruited 
from an appropriate source 
and no random selection was 
used to recruit patients
3. Was the sample size 
adequate/ Was sample size 
calculation performed?
Sample size calculation was performed and 
it was reported if this target was reached
No sample size calculation
4. Was the data analysis 
conducted with sufficient 
coverage of the identified 
sample?
Non-response was described AND a 
comparison between the responders and 
non-responders was performed.
If retrospective design, answer is yes
No information about 
response percentages was 
given or no comparison 
between responders and non-
responders was made.
5. Were objective, standard 
criteria used for the 
measurement of the 
condition?
Criteria were used for the diagnosis of SpA 
(for example (modified) New York criteria, 
ESSG criteria)
OR
A detailed description of how a case (for 
example sacroillitis) was defined is included 
in the manuscript.
OR
In case of use of ICD codes, a validation/
check was performed
No criteria were used and 
no description of how a case 
was defined is included in the 
manuscript.
6. Was the condition 
measured reliably?
Outcome assessor was qualified to use 
the case definition criteria (for example; 
medical specialist, trained research nurse)
Outcome assessor was not 
qualified to use the case 
definition criteria or it was 




Overview of the Risk of Bias Assessment per study
Item on Risk of Bias Assessment
Author Journal 1 2 3 4 5 6 Total Score
Al-Jarallah Inflammatory Bowel Diseases; 2012, 
18(9): 1655-1662
0 1 0 0 1 0 2
Al-Jarallah Int J Rheum Dis; 2013, 16(2): 134-138 0 1 0 1 1 0 3
Al-Shamali Digestion; 2003, 67(4): 218-224 1 1 0 1 0 0 3
Ansell BM Annals of the Rheumatic Diseases; 1964: 1 1 0 0 0 0 2
Arora Dig Dis Sci; 2010, 55(6): 1689-1695 1 1 0 1 0 0 3
Bandyopadhyay Indian J Gastroenterol; 2015, 34(5): 387-
394
1 1 0 0 1 1 4
Bardazzi Ital J Gastroenterol Hepatol; 1997, 29(6): 
520-524
0 1 0 0 1 1 3
Barreiro-De 
Acosta
Eur J Gastroenterol Hepatol; 2007, 19(1): 
73-78
0 1 0 1 1 1 4
Bernstein Am J Gastroenterol; 2001, 96(4): 1116-
1122
1 1 0 1 1 0 4
Beslek Rheumatol Int; 2009, 29(8): 955-957 0 0 0 0 1 1 2
Bruining Inflammatory Bowel Dis; 2008, 14(12): 
1701-1706
1 1 0 1 0 1 4
Christodoulou Dig Liver Dis; 2002, 34(11): 781-786 0 1 0 1 0 1 3
Davis ARTHRITIS RHEUM; 1978, 21(2): 234-7 0 1 0 0 1 0 2
De Vlam J Rheumatol; 2000, 27(12): 2860-2865 0 1 0 0 1 1 3
Dekker Saeys Annals of the Rheumatic Diseases; 1978, 
37(1): 33-35
1 1 0 1 1 1 5
D'Inca Dig Liver Dis; 2009, 41(8): 565-569 1 1 0 0 1 1 4
Dorofeyev Dig Dis; 2009, 27(4): 502-510 0 0 0 0 0 0 0
Fatemi J Res Med Sci; 2016, 21(3): 0 1 0 1 0 1 3
Fielding AM J GASTROENTEROL; 1986, 81(7): 524-
528
1 1 0 1 0 0 3
Gotler J. Magn. Reson. Imaging; 2015, 42(1): 
121-127
0 1 0 1 1 1 4
Greenstein MEDICINE; 1976, 55(5): 401-412 1 1 0 1 1 0 4
Haslock MEDICINE; 1973, 52(3): 217-225 1 1 0 0 0 0 2
Hwangbo Gut Liver; 2010, 4(3): 338-344 0 1 0 1 1 1 4
Indiveri S Afr Gastroenterol Rev; 2010, 8(3): 6-18 0 1 0 1 0 0 2
Isene Scand J Gastroenterol; 2015, 50(3): 300-
305
1 1 0 0 0 1 3
Kamo Mod Rheumatol; 2015, 25(3): 435-437 1 1 0 0 0 0 2
Karmiris J Crohn's Colitis; 2016, 10(4): 429-436 0 1 0 1 0 0 2
Kochhar Indian J Gastroenterol; 1991, 10(3): 88-89 1 1 0 1 1 0 4
Lakatos World J Gastroenterol; 2003, 9(10): 2300-
2307
1 1 0 0 1 1 4
Lanna Clin Rheumatol; 2008, 27(4): 503-509 1 1 0 0 1 1 4
Leclerc-Jacob Aliment Pharmacol Ther; 2014, 39(9): 
957-962
1 1 0 1 1 1 5
Liu Medicine (Baltimore); 2016, 95(28): 
e4267





Maeda J GASTROENTEROL; 1994, 29(5): 577-582 1 0 0 1 0 0 2
Mocelin Digestion; 2015, 91(4): 303-306 0 1 0 0 1 1 3
Modena CLIN EXP RHEUMATOL; 1988, 6(3): 221-
225
1 1 0 0 1 1 4
Münch Hepato- …; 1986: 1 1 0 0 1 1 4
Nguyen Am J Gastroenterol; 2006, 101(5): 1012-
1023
0 1 0 0 1 0 2
Orchard GUT; 1998: 1 1 0 1 1 0 4
Orchard Aliment Pharmacol Ther; 2009, 29(2): 
193-197
1 1 0 1 1 1 5
Ott World J Gastroenterol; 2014, 20(34): 
12269-12276
1 1 0 0 0 0 2
Ozdil Hepatogastroenterology; 2003, 50 Suppl 2 0 0 0 1 0 0 1
Ozdil Hepato-Gastroenterology; 2004, 51(57): 
768-770
0 1 0 1 0 0 2
Palm Rheumatology; 2001, 40(11): 1256-1261 1 1 0 0 1 1 4
Palm J Rheumatol; 2002, 29(3): 511-515 1 1 0 0 1 1 4
Paparo Abdom Imaging; 2012, 37(3): 326-337 0 1 0 1 1 1 4
Peeters J Gastroenterol Hepatol; 2008, 23(1): 132-
137
0 0 0 0 1 1 2
Pezerovic Coll Antropol; 2013, 37(3): 919-927 0 1 0 1 0 0 2
Pokharna Indian J Gastroenterol; 2004, 23(3): 89-90 1 1 0 1 1 0 4
Pongprasobchai J Med Assoc Thailand; 2001, 84(9): 1281-
1288
1 1 0 1 0 0 3
Queiro Clin Rheumatol; 2000, 19(6): 445-449 1 1 0 1 1 1 5
Rajput S AFR MED J; 1992, 81(5): 245-248 1 1 0 0 0 0 2
Repiso Ortega Rev Esp Enferm Dig; 2006, 98(7): 510-517 1 1 0 1 0 0 3
Ricart Inflammatory Bowel Diseases; 2004, 
10(3): 207-214
1 1 0 0 0 0 2
Salvarani Scand J Gastroenterol; 2001, 36(12): 
1307-1313
1 1 0 0 1 1 4
Scarpa J RHEUMATOL; 1992, 19(3): 373-377 1 1 0 1 1 1 5
Shivashankar J Rheumatol; 2012, 39(11): 2148-2152 1 1 0 1 1 1 5
Shivashankar J Rheumatol; 2013, 40(7): 1153-1157 1 1 0 1 1 1 5
Singh Indian J Gastroenterol; 2015, 1 1 0 1 0 0 3
Steer Journal of Rheumatology; 2003, 30(3): 
518-522
1 1 0 1 1 1 5
Suh J Korean Med Sci; 1998, 13(1): 39-43 0 1 0 1 1 0 3
Teh Ann Acad Med Singap; 1987, 16(3): 480-
487 (CD)
0 1 0 1 0 0 2
Teh Ann Acad Med Singap; 1987, 16(3): 474-
479 (UC)
1 1 0 1 0 0 3
Torres Intern J Inflamm; 2012, 1 0 0 1 0 0 2
Tozun J Clin Gastroenterol; 2009, 43(1): 51-57 1 1 0 0 0 0 2
Turkcapar Rheumatol Int; 2006, 26(7): 663-668 0 1 0 0 1 1 3
Vavricka Am J Gastroenterol; 2011, 106(1): 110-
119
1 1 0 0 1 0 3
Veloso J CLIN GASTROENTEROL; 1996, 23(1): 
29-34







Heterogeneity between groups: p = 0.002
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Heterogeneity betw en groups: p = 0.002
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0.10 (0.08, . 2)
0.00 (0.00, . 8)
0.08 (0.03, .14)
0.02 (0.01, . 5)
0.02 (0.01, . 4)
ES (95% CI)
0.18 (0.11, .25)
0.10 (0.06, . 6)







0.02 (0.00, . 7)
0.07 (0.04, .11)
0.02 (0.01, . 3)
0.21 (0.12, .33)
0.03 (0.01, . 8)
0.62 (0.50, .7 )
0.12 (0.05, .23)
0.03 (0.01, . 5)
0.12 (0.07, . 9)
0.39 (0.24, .55)
0.12 (0.04, .24)
0.01 (0.00, . 7)
0.20 (0.15, . 5)
0.16 (0.10, .24)
0.04 (0.02, . 7)
0.10 (0.02, .26)
0.03 (0.01, . 9)
0.01 (0.00, . 3)
0.16 (0.07, .29)
0.13 (0.10, . 7)





0.26 (0.11, .4 )




0.14 (0.07, .2 )
0.12 (0.05, .23)
0.00 (0.00, . 6)
0.07 (0.04, .12)
0.20 (0.12, . 9)
0.02 (0.01, . 3)




0.04 (0.02, . 8)
0.07 (0.05, . 9)
0.01 (0.00, . 2)
0.03 (0.01, . 7)
0.24 (0.09, .45)
0.06 (0.03, . 9)
0.02 (0.01, . 4)
0.03 (0.00, .12)




































































Wagtmans Am J Gastroenterol; 2001, 96(5): 1541-
1546
0 0 0 1 0 0 1
Yi Eur J Gastroenterol Hepatol; 2012, 24(12): 
1424-1429
1 1 0 1 0 0 3
Yuksel Dig Dis Sci; 2011, 56(1): 183-187 1 1 0 1 0 1 4
Zippi World J Gastroenterol; 2014, 20(46): 
17463-17467







Heterogeneity between groups: p = 0.002
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Heterogeneity between groups: p = 0.006
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Heterogeneity between groups: p = 0.076


















































































Subtotal  (I^2 = 99.78%, p = 0.00)
Haslock (1973)
Ott (2014)













































































































































































Forestplot	of	 he	preval nc 	of	Peripheral	Arthritis	of	all	included	studi s	
Heterogeneity between roups: p = 0.076
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Heterogeneity between groups: p = 0.006
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Heterogeneity between groups: p = 0.076
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Musculoskeletal Complaints cause Significant Burden in 
Patientswith Inflammatory Bowel Disease: 
A Survey among Patients
M.C. Karreman
J.M.W. Hazes






























Crohn’s	 disease	 (CD)	 and	 ulcerative	 colitis	 (UC).	 IBD	 often	 manifests	 at	 young	 age	 and	 it	 can	 be	
accompanied	by	a	number	of	extra-intestinal	manifestations	which	have	a	significant	impact	on	health	











health	 related	quality	 of	 life	 (HRQoL).1-3,13	 Less	 is	 known	however	 about	 the	 impact	 of	 these	MSC	
complaints	on	patients	with	IBD.	Because	we	wanted	to	assess	this	 impact	 in	a	real	 life	unselected	
population	of	 IBD	patients,	we	selected	patients	 from	a	primary	care	setting.	The	objective	of	 this	





Between	December	 2014	 and	 August	 2015,	 81	GPs	 from	 the	 Southwest	 of	 the	Netherlands	were	
recruited	to	participate	in	our	study.	These	GPs	selected	all	their	IBD	patients	aged	18	to	55	years	from	
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questionnaires	 on	 paper,	 they	 received	 the	 questionnaires	 on	 paper.	 The	 questionnaires	 included	
questions	 about	 IBD	 (such	 as	 type	 of	 IBD,	 characteristics	 and	 current	 treatment),	 about	
musculoskeletal	complaints,	quality	of	life	and	work	participation.	






tendon	and/or	 lower	back	complaints.	 For	each	of	 the	 three	domains	of	MSC,	 the	duration	of	 the	
complaints	was	asked,	as	well	as	medication	use	and	pain	in	the	preceding	7	days	(VAS	scale	0-100,	
where	0	indicates	no	pain	and	100	indicates	worst	pain	imaginable).	If	patients	suffered	from	lower	
back	 complaints,	 they	 also	 completed	 the	 Assessment	 of	 SpondyloArthritis	 International	 Society	















IBDQ	 (Inflammatory	Bowel	Disease	Questionnaire)	 is	 the	most	widely	 used	 and	 validated	disease-
specific	 quality	 of	 life	 questionnaire	 for	 patient	 with	 IBD.17-19	 It	 consists	 of	 32	 questions	 and	 the	
responses	are	graded	on	a	7	point	Likert	scale,	giving	a	possible	score	range	from	32	to	224,	where	a	
higher	score	represents	better	HRQoL.	The	questionnaire	can	be	subdivided	in	four	different	domains:	
bowel	 symptoms	 (10	 questions,	 score	 0-70),	 systemic	 symptoms	 (5	 questions,	 score	 0-35),	 social	
function	(5	questions,	score	0-35)	and	emotional	function	(12	questions,	score	0-84).	The	individual	
scores	for	the	different	domains	are	calculated	as	average	scores	per	domain.	
SF-36	 (Short	 Form	 36)	 is	 a	 widely	 used	 questionnaire	 on	 general	 HRQoL	 with	 high	 validity	 and	
reliability.20	It	consists	of	36	questions	and	the	score	is	presented	in	the	following	8	domains:	physical	
functioning,	 role	 physical	 (limitations	 due	 to	 physical	 problems),	 bodily	 pain,	 vitality,	 social	






All	patients	answered	questions	about	 their	highest	 completed	educational	 level;	 low	 (elementary	
school),	medium	(high	school)	or	high	(university).	Current	work	status	(employed	or	not	employed)	
and	work-disability	were	also	asked	for	and	compared	with	the	general	Dutch	population.22	To	assess	
















In	 total,	 535	 patients	 with	 IBD	 aged	 18-55	 years	 of	 age	 (37.9%	 male)	 were	 selected	 out	 of	 the	
databases	of	the	81	participating	GPs.	In	the	process	of	inviting	the	patients	to	participate,	23	(4.3%)	
reported	 not	 to	 have	 IBD,	 so	 eventually	 512	 IBD	 patients	 selected	 by	 the	 GP	 were	 eligible	 to	





questionnaires	 on	 paper,	 they	 received	 the	 questionnaires	 on	 paper.	 The	 questionnaires	 included	
questions	 about	 IBD	 (such	 as	 type	 of	 IBD,	 characteristics	 and	 current	 treatment),	 about	
musculoskeletal	complaints,	quality	of	life	and	work	participation.	






tendon	and/or	 lower	back	complaints.	 For	each	of	 the	 three	domains	of	MSC,	 the	duration	of	 the	
complaints	was	asked,	as	well	as	medication	use	and	pain	in	the	preceding	7	days	(VAS	scale	0-100,	
where	0	indicates	no	pain	and	100	indicates	worst	pain	imaginable).	If	patients	suffered	from	lower	
back	 complaints,	 they	 also	 completed	 the	 Assessment	 of	 SpondyloArthritis	 International	 Society	















IBDQ	 (Inflammatory	Bowel	Disease	Questionnaire)	 is	 the	most	widely	 used	 and	 validated	disease-
specific	 quality	 of	 life	 questionnaire	 for	 patient	 with	 IBD.17-19	 It	 consists	 of	 32	 questions	 and	 the	
responses	are	graded	on	a	7	point	Likert	scale,	giving	a	possible	score	range	from	32	to	224,	where	a	
higher	score	represents	better	HRQoL.	The	questionnaire	can	be	subdivided	in	four	different	domains:	
bowel	 symptoms	 (10	 questions,	 score	 0-70),	 systemic	 symptoms	 (5	 questions,	 score	 0-35),	 social	
function	(5	questions,	score	0-35)	and	emotional	function	(12	questions,	score	0-84).	The	individual	
scores	for	the	different	domains	are	calculated	as	average	scores	per	domain.	
SF-36	 (Short	 Form	 36)	 is	 a	 widely	 used	 questionnaire	 on	 general	 HRQoL	 with	 high	 validity	 and	
reliability.20	It	consists	of	36	questions	and	the	score	is	presented	in	the	following	8	domains:	physical	
functioning,	 role	 physical	 (limitations	 due	 to	 physical	 problems),	 bodily	 pain,	 vitality,	 social	






All	patients	answered	questions	about	 their	highest	 completed	educational	 level;	 low	 (elementary	
school),	medium	(high	school)	or	high	(university).	Current	work	status	(employed	or	not	employed)	
and	work-disability	were	also	asked	for	and	compared	with	the	general	Dutch	population.22	To	assess	
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regard	 to	medication,	 the	majority	 (around	70%)	used	 some	kind	of	medication	 for	 their	 IBD	with	
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Table 1 Baseline Characteristics
Total Crohn’s Disease Ulcerative Colitis
No of Patients, n (%)# 338 154 (45.6) 152 (45.0)
Age, mean (SD) 42.3 (9.3) 41.7 (9.7) 42.5 (9.0)
Male sex, n (%) 85 (25.1) 32 (20.8) 44 (28.9)
Dutch nationality, n (%) 333 (98.5) 153 (99.4) 148 (97.4)
Median duration IBD, years (IQR) 10 (5-18) 12 (7-21) 9 (4-15)
Level of Education 
Low, n (%) 32 (9.5) 10 (6.5) 17 (11.3)
Intermediate, n (%) 175 (52.1) 81 (52.9) 75 (49.7)
High, n (%) 129 (38.4) 62 (40.5) 59 (39.1)
Medication IBD, n (%)
None 94 (27.8) 41 (26.6) 41 (27.0)
Mesalazine 119 (35.2) 27 (17.5) 83 (54.6)
Corticosteroids 41 (12.1) 22 (14.3) 14 (9.2)
Immunosuppressants$ 99 (29.3) 59 (38.3) 35 (23.0) 
Anti-TNF* 69 (20.4) 44 (28.6) 17 (11.2)
Other 16 (4.7) 8 (5.2) 5 (3.3)
Bowel surgery, n (%)
None 245 (72.5) 84 (54.5) 135 (88.8)
Partial resection 61 (18.0) 57 (37.0) 3 (2.0)
Stoma 17 (5.0) 7 (4.5) 8 (5.3)
Pouch 9 (2.7) 0 3 (2.0)
Other 6 (1.8)  6 (3.9) 3 (2.0)
# The remaining 32 patients suffered from unclassified IBD and were disregarded for the scope of this study. $ 







































































into	 joint,	 tendon	 or	 back	 complaints,	 all	 three	 domains	 of	MSC	 showed	 comparable	 decrease	 in	
subscores	compared	with	 the	Dutch	 reference	population.	As	 in	 the	 IBDQ,	 the	scores	 for	UC	were	
slightly	 higher	 than	 the	 scores	 for	 CD.	 Looking	 into	 non-inflammatory	 and	 inflammatory	 (positive	
ASAS-IBP	 or	 rheumatological	 diagnosis)	MSC,	 the	 scores	 on	 both	 IBDQ	 and	 SF-36	 were	 lower	 for	
patients	with	inflammatory	MSC	than	for	patients	with	non-inflammatory	MSC.	
	 	
Table 2 Characteristics of Musculoskeletal Complaints in patients with IBD
IBD (n=338) CD (n=154) UC (n=152)
Musculoskeletal Complaints, n (%) 274 (81.1) 133 (86.4) 114 (75.0)
Rheumatological Diagnosis, n (%) 36 (10.7) 20 (13.0) 11 (7.2)
Joint complaints
No of Patients, n (%) 214 (63.3) 109 (70.8) 81 (53.3)
Duration of complaints, median (IQR) years 7 (3-15) 7 (3-13) 6 (2-15)
Pain in preceding week, mean (SD) 43.4 (24.7) 44.6 (24.7) 41.3 (25.2)
HAQ score, median (IQR) 0.38 (0.13-0.63) 0.5 (0.13-0.75) 0.13 (0-0.5)
(n=127) (n=72) (n=45)
Medication use, n (%) 110 (51.4) 54 (40.6) 42 (51.9)
Paracetamol, n (%) 79 (71.8) 40 (74.1) 30 (71.4)
NSAIDs, n (%) 29 (26.4) 11 (20.4) 12 (28.6)
Morphinomimetics, n (%) 28 (25.5) 19 (35.2) 5 (11.9)
Tendon Complaints
No of Patients, n (%) 104 (30.8) 43 (27.9) 47 (30.9)
Duration of complaints, median (IQR) years 4 (2-10) 5 (1-15) 3 (2-8)
Pain in preceding week, mean (SD) 42.8 (25.9) 48.1 (24.7) 39.7 (25.7)






Medication use, n (%) 52 (50%) 22 (51.2) 23 (48.9)
Paracetamol, n (%) 43 (82.7) 19 (86.4) 20 (87.0)
NSAIDs, n (%) 14 (26.9) 6 (27.3) 4 (17.4)
Morphinomimetics, n (%) 11 (21.2) 7 (31.8) 2 (8.7)
Lower Back Complaints
No of Patients, n (%) 203 (60.1) 99 (64.3) 85 (55.9)
Duration of complaints, median (IQR) years 10 (4-20) 8 (3-15) 10 (4-20)
Positive ASAS-IBP, n (%) 75 (36.9) 30 (30.3) 37 (43.5)
Pain in preceding week, mean (SD) 39.0 (27.1) 39.9 (25.9) 36.4 (28.6)
RMDQ score, median (IQR) 4 (1-10) 5 (2-10) 3 (1-9)
Medication use, n (%) 86 (42.4) 41 (41.4) 36 (42.4)
Paracetamol, n (%) 66 (76.7) 36 (87.8) 24 (66.7)
NSAIDs, n (%) 21 (24.4) 8 (19.5) 9 (25.0)
Morphinomimetics, n (%) 25 (29.1) 15 (36.6) 9 (25.0)
























































into	 joint,	 tendon	 or	 back	 complaints,	 all	 three	 domains	 of	MSC	 showed	 comparable	 decrease	 in	
subscores	compared	with	 the	Dutch	 reference	population.	As	 in	 the	 IBDQ,	 the	scores	 for	UC	were	
slightly	 higher	 than	 the	 scores	 for	 CD.	 Looking	 into	 non-inflammatory	 and	 inflammatory	 (positive	































status	 in	 the	 general	 Dutch	 population	 (93.2%).	 Of	 the	 patients	who	were	 currently	 unemployed,	
45.6%	 (n=41)	 reported	 to	 be	 work-disabled,	 of	 whom	 82.9%	 were	 80-100%	 work-disabled.	 If	
comparing	 IBD	 patients	 with	 and	 without	 MSC	 differences	 can	 be	 shown.	 Table	 4	 shows	 the	
percentages	 of	 absenteeism	 and	 presenteism	 and	 the	 mean	 work	 productivity	 loss	 and	 activity	




was	comparable	 to	 the	percentage	of	absenteeism	caused	by	 IBD.	The	percentage	of	presenteism	
(=reduced	effectiveness	while	at	work)	caused	by	IBD	was	36.4%	compared	to	53.1%	caused	by	lower	
back	complaints,	61.2%	for	joint	complaints	and	63.4%	for	tendon	complaints.	Both	work	productivity	
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Table 3 Mean scores of the IBDQ questionnaire in IBD patients with and without MSC
IBD CD UC
No MSC MSC No MSC MSC No MSC MSC
Number of Patients, n 64 274 21 133 38 114
Total score
(range 0-224)
183.6 (26.7) 165.4 (27.8) 180.1 (30.5) 158.2 (26.9) 187.0 (24.7) 174 (26.2)
Bowel Symptoms
(range 0-70)
58.0 (8.6) 52.9 (8.9) 58.6 (9.2) 51.1 (8.7) 58.3 (8.5)# 55.4 (8.6)#
Systemic Symptoms
(range 0-35)
25.5 (6.2) 21.2 (5.9) 25.4 (6.0) 19.8 (5.7) 26.1 (6.4) 22.7 (5.5)
Social Function
(range 0-35)
31.9 (4.9) 29.3 (5.9) 30.2 (5.8) 27.4 (6.4) 32.9 (4.1) 31.3 (4.5)
Emotional Function
(range 0-84)
68.2 (10.1) 62.1 (11.6) 66.0 (11.6) 59.9 (11.4) 69.7 (9.4) 64.6 (11.5)
For all differences between No MSC and MSC p-value is lower than 0.05, except for #
	
PF RF BP V SF RE MH GH
Dutch	Reference	Population 82,5 77,7 80,2 65,9 84,2 87,2 77,3 69,4
UC 82,5 70,8 67,2 55,8 78,9 80,0 73,5 52,3
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Dutch	Reference	Population 82,5 77,7 80,2 65,9 84,2 87,2 77,3 69,4
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This	study	demonstrates	that	MSC	are	frequent	 in	patients	with	 IBD	and	have	great	 impact	on	the	
burden	of	disease.	The	impact	of	these	MSC	is	demonstrated	by	significantly	lower	scores	in	quality	of	
life,	 in	both	physical	and	mental	health	domains.	With	regard	to	work	status	and	productivity,	 IBD	



















show	 decreased	 quality	 of	 life	 as	measured	with	 the	 SF-36	 and	 short-IBDQ	 in	 patients	 with	 joint	
































Table 4 Work status and productivity in IBD patients with or without joint, tendon or lower back 
complaints







Activity Impairment, mean (SD) 0.17 (0.24) 0.36 (0.27) 0.33 (0.27) 0.29 (0.28)
Not Working 14 (20.3) 67 (31.3) 33 (31.7) 56 (27.6)
Work-disabled, n (%) 1 (1.4) 38 (17.8) 19 (18.3) 33 (16.3)
80-100%, n (%) Unknown 27 (71.1) 17 (89.5) 28 (84.8)
Working 55 (79.7) 147 (68.7) 71 (68.3) 147 (72.4)
Absenteism, n/N (%) 5/51 (9.8) 14/131 (10.7) 6/61 (9.8) 8/129 (6.2)
Presenteism, n (%) 20 (36.4) 90 (61.2) 45 (63.4) 78 (53.1)
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In	conclusion,	EIMS	like	MSC	have	significant	 impact	on	the	quality	of	 life	and	work	productivity	 in	
patients	with	IBD.	The	reduced	quality	of	life	found	in	IBD	seems	to	be	explicitly	influenced	by	MSC.	
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Awareness of Spondyloarthritis in General Practitioners 
and their Patients: 














or	 inflammatory	bowel	disease	 (IBD).	A	survey	was	developed	and	sent	out	 to	GPs	and	patients	 in	










Conclusions.	 Overall,	 recognition	 of	 inflammatory	 disease	 by	 GPs	 is	 suboptimal,	 with	 about	 50%	
recognizing	less	than	half	of	the	features	known	to	be	indicative	of	inflammatory	joint	or	back	pain.	In	
addition,	less	than	half	of	the	patients	with	PSO	or	IBD	are	aware	of	the	possibility	of	developing	SpA.	

























key	 factor	 in	 seeking	 help	 at	 the	 onset	 of	 RA.14-16	 By	 educating	 patients	 at	 risk,	 patients	 could	 be	
informed	 to	 consult	 a	 GP	 when	 they	 experience	 MSC.	 Where	 internationally	 campaigns	 for	
rheumatoid	 arthritis	 increased	 the	 awareness	 in	 both	 GPs	 and	 patients,	 the	 focus	 of	 SpA	 lags	
behind.17,18				
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their	 time	 to	 complete	 the	 survey.	 In	 addition,	 the	 survey	was	handed	out	 during	 several	 plenary	
training	sessions	for	GPs	organized	by	different	hospitals.	Approximately	two	weeks	after	receiving	
the	survey	either	during	a	training	or	by	mail,	GP	practices	were	called	by	medical	students	to	remind	




























The	 final	 survey	 included	 questions	 about	 the	 recognition	 of	 signs	 and	 symptoms	 that	 indicate	
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Table 1  Proportion of GPs who identified correct signs of inflammatory joint and back pain (n=185)
Signs of inflammatory pain Joint Back
Insidious onset of complaints, n (%)            53 (28.7) 90 (48.7)
Symptom duration>3 months, n (%)           57 (30.8) 93 (50.3)
Pain improved with exercise, n (%)             25 (13.5) 39 (21.1)
Pain not relieved by rest, n (%) 30 (16.2) 40 (21.6)
Pain relieved by NSAIDs, n (%)                     162 (87.6) 152 (82.2)
Morning Stiffness>30min, n (%)   142 (76.8) 139 (75.1)
Nocturnal Pain, n (%)                                     Not Applicable 145 (78.4)





































































































































Table 2 Reasons to check rheumatoid factor, ACPA and HLA-B27 status
Rheumatoid Factor ACPA HLA-B27
Every patient with complaints, n (%) 1 (0.54) 0 1 (0.54)
Patients who often return with complaints, n (%) 103 (55.7) 94 (50.8) 20 (10.8)
Patients with inflammatory complaints, n (%) 90 (48.7) 104 (56.2) 64 (34.6)
Patients with a positive family history, n (%) 51 (27.6) 48 (26.0) 20 (10.8)
Never, n (%) 28 (15.1) 22 (11.9) 82 (44.3)
I don’t know what it is, n (%) 0 4 (2.2) 5 (2.7)
Table 3 Proportion of GPs who ask about associated SpA features when a patient presents with 
inflammatory joint or back pain (n=185)
Associated SpA Features
Psoriasis, n (%) 155 (83.8)
Inflammatory Bowel Disease, n (%) 134 (72.4)
Enthesitis, n (%) 35 (18.9)
Dactylitis, n (%) 35 (18.9)
Uveitis, n (%) 116 (62.7)





























This	 survey	 among	 GPs	 and	 patients	 at	 risk	 for	 SpA	 in	 the	 Netherlands	 demonstrates	 that	 the	
knowledge	and	awareness	of	patients	for	axial	and	peripheral	SpA	could	be	improved.	Almost	60%	of	



























This	 survey	 among	 GPs	 and	 patients	 at	 risk	 for	 SpA	 in	 the	 Netherlands	 demonstrates	 that	 the	
knowledge	and	awareness	of	patients	for	axial	and	peripheral	SpA	could	be	improved.	Almost	60%	of	
GPs	 did	 not	 recognize	 half	 of	 the	 features	 indicative	 of	 inflammatory	 peripheral	 joint	 disease,	 for	
Table 4 Level of Awareness in Patients with Psoriasis or IBD
Psoriasis (n=552) IBD (n=344)
% Awareness 43.1 41.9
       % Informed by GP 13.5 1.4
       % Informed by medical specialist 24.4 40.3
       % Via family and friends 18.5 9.7
       % By information gathering 34.0 39.6
       % Patient organization 8.4 2.8
       % Other 1.3 6.3
inflammatory	axial	disease	this	percentage	is	slightly	lower	but	still	40%.	More	than	half	of	the	GPs	
associated	SpA	this	solely	with	the	axial	manifestations	and	especially	dactylitis	and	enthesitis	were	









GPs	 to	 assess	 how	 they	 identify	 peripheral	 arthritis.21	 They	 showed	 that	 GPs	 often	 evaluate	 the	
classical	 symptoms	 of	 arthritis;	 pain,	 swelling,	 warmth,	 redness	 and	 loss	 of	 function,	 while	
rheumatologists	 work	 with	 the	 inflammatory	 features	 as	 mentioned	 in	 this	 paper.	 In	 about	 20%	
morning	stiffness	and	family	history	were	reported,	while	about	75%	of	GPs	from	this	survey	said	they	
ask	for	morning	stiffness	
Regarding	 the	 inflammatory	 back	 pain,	 we	 show	 low	 knowledge	 of	 the	 criteria	 for	
inflammatory	axial	disease.	This	 is	 in	 line	with	Van	Onna	et	al	who	showed	 insufficient	knowledge	
about	axial	SpA	in	a	qualitative	study	in	primary	care	in	the	Netherlands	by	interviewing	GPs.22	The	
results	of	our	study	are	slightly	different	from	the	results	of	the	survey	in	the	United	Kingdom,	where	
17%	 of	 GPs	 was	 unable	 to	 recognize	 more	 than	 half	 of	 the	 features.20	 This	 difference	 could	 be	
explained	by	the	fact	that	the	study	from	the	UK	is	eight	years	old	and	awareness	might	have	improved	
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of	 having	 SpA.28-30	 However,	 guidelines	 and	 education	 alone	 does	 not	 seem	 to	 be	 sufficient.	 Two	










symptoms	 from	 inflammatory	 rheumatic	 disease	 should	 be	 improved	 in	 order	 to	 facilitate	 early	
diagnosis	 and	 treatment.	 More	 research	 is	 necessary	 to	 analyse	 the	 impact	 of	 adequate	 referral	
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Performance of Screeningtools for Psoriatic Arthritis: 
A Cross-sectional study in Primary Care
M.C. Karreman
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Psoriatic	 arthritis	 (PsA)	 is	 an	 inflammatory	 joint	 disease,	 associated	 with	 psoriasis.1	 Increasing	
evidence	 suggests	 that	 diagnosing	 PsA	 early	 and	 subsequently	 provide	 early	 treatment,	 improves	
patients’	outcomes	substantially.2-5	Since	in	the	majority	of	cases	the	symptoms	of	the	skin	precede	
the	musculoskeletal	 symptoms,	an	opportunity	 for	screening	arises.6	Physicians	who	treat	patients	
with	 psoriasis,	 like	 general	 practitioners	 (GPs)	 and	 dermatologists,	 should	 pay	 attention	 to	 these	
musculoskeletal	 symptoms,	 as	 timely	 referral	 to	 a	 rheumatologist	 can	 assure	 early	 diagnosis	 and	
adequate	treatment.	
To	 enhance	 early	 recognition	 by	 dermatologists	 and	 GPs	 several	 screening	 questionnaires	 were	
developed,	like	the	PEST,	PASE	and	EARP.7-9	These	were	mostly	developed	in	secondary	care	and	until	












for	 psoriasis).14	 The	 ICPC	 is	 widely	 used	 for	 coding	 signs	 and	 symptoms	 in	 primary	 care	 in	 the	
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Patients	 were	 asked	 to	 complete	 a	 set	 of	 questionnaires	 just	 before	 clinical	 evaluation.	 Three	
screening	 questionnaires	 were	 completed;	 PEST	 (Psoriasis	 Epidemiology	 Screening	 Tool),	 PASE	




validated	 multiple	 times	 in	 secondary	 care	 and	 its	 sensitivity	 ranges	 from	 0.28	 to	 0.77	 while	 its	
specificity	ranges	from	0.37	to	0.98.10-13	
PASE	was	developed	in	the	USA	and	consists	of	15	questions	with	a	5-point	answer	scale	(from	
strongly	disagree	 to	strongly	agree).	The	cut-off	was	set	at	47	 in	 the	development,	but	 in	 the	 first	
validation	by	the	same	group	a	cut-off	value	of	44	provided	better	sensitivity	and	specificity.7,16	This	













focusing	 on	 psoriasis,	 musculoskeletal	 complaints	 and	 other	 factors	 like	 family	 history	 and	
comorbidities.	Physical	examination	focused	on	the	skin,	nails,	joints	and	entheses.	Psoriasis	severity	
was	 assessed	 by	 the	 PASI	 score.	 The	 nails	 were	 visually	 inspected	 and	 in	 case	 of	 abnormalities	 a	
photograph	 was	 taken	 which	 later	 on	 was	 evaluated	 for	 the	 presence	 of	 nail	 psoriasis	 by	 a	
dermatologist.	The	joints	were	evaluated	for	tenderness	and	swelling	using	the	66/68	joint	count.	For	
the	 evaluation	 of	 the	 entheses,	 the	 LEI	 and	MASES	 scores	were	 used.	 These	 scores	 are	 based	 on	
tenderness	 upon	manual	 palpation.	 If	 clinical	 evaluation	 resulted	 in	 at	 least	 one	 tender	 enthesis,	
patients	were	referred	for	an	ultrasonographic	examination	by	an	independent	trained	examiner	using	







are	 required:	 the	 presence	 of	 psoriasis	 (current	 (2	 points)	 or	 history),	 presence	 of	 psoriatic	 nail	
dystrophy,	absence	of	rheumatoid	factor,	dactylitis	(diagnosed	by	rheumatologist)	and	radiographic	
evidence	of	juxtaarticular	new	bone	formation.	The	presence	of	peripheral	arthritis	and	axial	disease	
were	 confirmed	 by	 a	 rheumatologist.	 Since	 there	 is	 no	 commonly	 accepted	 clinical	 definition	 for	
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Mean Age, years (±SD) 55.9 (14.0) 47.4 (10.7) 58 (12.3)
Male sex, n (%) 216 (51.4) 8 (47.1) 17 (47.2)
Body Mass Index, mean (±SD) 27.8 (4.8) 27.9 (6.2) 30.0 (4.1)
Median Psoriasis Symptom Duration, years (IQR) 15 (8-30) 15 (4-30) 20 (11-37)
Psoriasis Diagnosis by Dermatologist, n (%) 302 (71.9) 13 (76.5) 31 (86.1)
Nail psoriasis, n (%) 64 (15.2) 5 (29.4) 2 (5.6)
PASI, median (IQR) 2.2 (1-4) 3 (1.3-4) 3.1 (1.7-4.4)
Median MSC Symptom Duration, years (IQR)                          
Joints 8 (4-14) 12.5 (2-23) 10 (5-25)
Lower Back 12 (5-25) 18 (9-25) 33 (14-41)
LEI, median (IQR) 0 (0-0) 0 (0-1) 1 (1-2)
MASES, median (IQR) 0 (0-0) 0 (0-3) 2 (0-3)
PsA=Psoriatic Arthritis, PASI=Psoriasis Area&Severity Index, MSC=musculoskeletal complaints, LEI=Leeds 
Enthesitis Index, MASES= Maastricht Ankylosing Spondylitis Enthesitis Score
*Axial manifestations & arthritis are the patients who were diagnosed as having PsA by the rheumatologist. 





The	 sensitivity	 and	 specificity	 were	 calculated	 separately	 for	 enthesitis	 and	 axial	 or	 peripheral	
manifestations	of	PsA.	These	results	were	very	similar	and	can	be	found	in	supplemental	file	S1.	When	
only	selecting	patients	without	systemic	therapy	for	their	psoriasis	(5	methotrexate,	4	ciclosporin,	4	
etanercept	 &	 5	 adalumimab),	 the	 sensitivity	 increased	 slightly	 with	 approximately	 0.02	 while	 the	
specificity	remained	more	or	less	the	same	(see	supplemental	file	S1).		
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Improving	early	 recognition	of	PsA	 in	primary	and	secondary	care	 is	challenging.	Given	the	
different	performance	of	the	screeningtools,	the	question	what	would	be	best	to	do	in	clinical	practice	
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Table 2 Sensitivity and specificity of PEST, PASE & EARP


































Peripheral Arthritis (n=12) 2 (16.7) 4 (33.3) 4 (33.3) 2 (16.7)
Enthesitis (n=36) 12 (33.3) 13 (36.1) 16 (44.4) 4 (11.1)




harm	 and	 benefit	 of	 the	 decision	 after	 screening	 and	 the	 prior	 probability	 of	 having	 the	 disease.	





























in	 the	 development	 study	 (0.85),	 the	 specificity	 was	 considerably	 lower	 with	 0.34	 (vs	 0.92	 in	
development	study).9		
As	we	did	one	of	the	first	validations	in	primary	care,	it	is	interesting	to	put	this	in	perspective	
with	 studies	 that	 have	 validated	 the	 tools	 in	 secondary	 care.	 Three	 out	 of	 four	 studies	 showed	






















tools	 in	 primary	 care.	Most	 developments	 (except	 PEST)	 and	 validations	 have	 been	 performed	 in	
secondary	care.	Secondly,	our	study	is	the	first	validation	of	the	EARP	questionnaire	and	we	have	a	
fairly	large	and	complete	database	of	psoriasis	patients	at	risk	for	PsA.	With	regard	to	limitations,	we	
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Table S2.1S Performance of Screeningtools in non-DMARD-users























Table S2.2 Performance of Screeningtools in patients with articular or axial disease
Cut off True Positive False 
positive
True negative False 
negative
Sensitivity Specificity
















Table S2. Performance of Screeningtools in patients with Entheseal Disease
Cut off True Positive False 
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True negative False 
negative
Sensitivity Specificity
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Table S3  Parameter estimates used in the sensitivity analysis for the non-responders (n=891)
Scenario 1 Scenario 2 Scenario 3
First 
step:
MSC prevalence among 
responders (n=1673; 49.2%)
MSC prevalence among those 
returning the reply slip but did 
not want to participate (n=704; 
23.3%)
MSC prevalence among those 
returning the reply slip but did 




PsA prevalence among MSC 
(n=823; 9.8%)
PsA prevalence among MSC ( 
n=823; 9.8%)
PsA among those with MSC 





















































Which Tool to use when Screening for Psoriatic Arthritis 
in Psoriasis Patients in a Primary Care Setting? 
M.C. Karreman
A.E.A.M. Weel














this,	 several	 screening	 tools	 have	 been	 developed	with	 suboptimal	 performance.	 Recently,	 a	 new	




Methods.	 Data	 from	 the	 SENSOR	 study	 was	 used,	 a	 cross-sectional	 study	 in	 adult	 primary	 care	





questionnaires	 ranged	 between	 0.67-0.69	 and	 sensitivities	 between	 0.30-0.51	 in	 our	 primary	 care	
population,	 whereas	 the	 specificities	 were	 between	 0.74-0.86.	 On	 sensitivity	 the	 PEST	 (0.68),	













timely	 treatment,	 it	 is	 important	 to	 recognize	 these	patients	early.1,2	Over	 the	 last	couple	of	years	
several	screeningtools	were	developed	in	order	to	enhance	this	early	recognition	of	patients	with	PsA.	




care	 setting.3	 They	 found	 lower	 sensitivities	 and	 specificities	 than	 previously	 reported	 and	 AUCs	
around	0.6.	However,	the	prevalence	of	PsA	increased	according	to	the	number	of	positively	answered	
questionnaires.	This	 led	 them	to	develop	a	new	screening	questionnaire	 (CONTEST	questionnaire),	
based	 on	 the	 best	 performing	 items	 of	 the	 individual	 questionnaires.7	 	 Since	 this	 is	 yet	 another	
screening	tool,	the	question	raises	which	tool	could	best	be	used	to	screen	psoriasis	patients	for	the	
presence	of	PsA.	Various	 validations	have	been	performed,	but	mostly	 in	 secondary	 care	 settings.	
However,	primary	care	could	also	play	an	important	role	in	screening.	The	objective	of	this	study	was	





Between	 June	 2013	 and	March	 2014	 a	 cross-sectional	 study	 in	 primary	 care	 was	 performed,	 the	
SENSOR	 study.	Ninety-seven	GPs	 from	 the	greater	Rotterdam	area	participated	and	 selected	 their	
adult	 psoriasis	 patients	 using	 ICPC	 code	 S91	 (International	 Classification	 of	 Primary	 Care	 code	 for	
psoriasis).8	 All	 identified	 psoriasis	 patients	 received	 an	 invitation	 from	 their	 GP	 asking	 them	 to	
participate	in	the	study.	If	patients	were	willing	to	participate	they	were	contacted	by	telephone	by	a	
trained	 interviewer	 to	verify	 the	presence	of	musculoskeletal	 complaints	 (either	 joints,	 tendons	or	
lower	back).	The	interviewer	also	verified	whether	they	were	diagnosed	with	psoriasis	and	sufficient	
knowledge	of	 the	Dutch	 language	 to	complete	 the	questionnaires.	Ethics	approval	 from	the	Dutch	
Medical	Ethical	Committee	 (M12-1275)	was	obtained	as	well	as	written	 informed	consent	 from	all	











this,	 several	 screening	 tools	 have	 been	 developed	with	 suboptimal	 performance.	 Recently,	 a	 new	




Methods.	 Data	 from	 the	 SENSOR	 study	 was	 used,	 a	 cross-sectional	 study	 in	 adult	 primary	 care	





questionnaires	 ranged	 between	 0.67-0.69	 and	 sensitivities	 between	 0.30-0.51	 in	 our	 primary	 care	
population,	 whereas	 the	 specificities	 were	 between	 0.74-0.86.	 On	 sensitivity	 the	 PEST	 (0.68),	













timely	 treatment,	 it	 is	 important	 to	 recognize	 these	patients	early.1,2	Over	 the	 last	couple	of	years	
several	screeningtools	were	developed	in	order	to	enhance	this	early	recognition	of	patients	with	PsA.	




care	 setting.3	 They	 found	 lower	 sensitivities	 and	 specificities	 than	 previously	 reported	 and	 AUCs	
around	0.6.	However,	the	prevalence	of	PsA	increased	according	to	the	number	of	positively	answered	
questionnaires.	This	 led	 them	to	develop	a	new	screening	questionnaire	 (CONTEST	questionnaire),	
based	 on	 the	 best	 performing	 items	 of	 the	 individual	 questionnaires.7	 	 Since	 this	 is	 yet	 another	
screening	tool,	the	question	raises	which	tool	could	best	be	used	to	screen	psoriasis	patients	for	the	
presence	of	PsA.	Various	 validations	have	been	performed,	but	mostly	 in	 secondary	 care	 settings.	
However,	primary	care	could	also	play	an	important	role	in	screening.	The	objective	of	this	study	was	





Between	 June	 2013	 and	March	 2014	 a	 cross-sectional	 study	 in	 primary	 care	 was	 performed,	 the	
SENSOR	 study.	Ninety-seven	GPs	 from	 the	greater	Rotterdam	area	participated	and	 selected	 their	
adult	 psoriasis	 patients	 using	 ICPC	 code	 S91	 (International	 Classification	 of	 Primary	 Care	 code	 for	
psoriasis).8	 All	 identified	 psoriasis	 patients	 received	 an	 invitation	 from	 their	 GP	 asking	 them	 to	
participate	in	the	study.	If	patients	were	willing	to	participate	they	were	contacted	by	telephone	by	a	
trained	 interviewer	 to	verify	 the	presence	of	musculoskeletal	 complaints	 (either	 joints,	 tendons	or	
lower	back).	The	interviewer	also	verified	whether	they	were	diagnosed	with	psoriasis	and	sufficient	
knowledge	of	 the	Dutch	 language	 to	complete	 the	questionnaires.	Ethics	approval	 from	the	Dutch	
Medical	Ethical	Committee	 (M12-1275)	was	obtained	as	well	as	written	 informed	consent	 from	all	







a	 trained	 research	nurse.	Beforehand,	all	patients	 completed	a	 set	of	questionnaires	 including	 the	
screening	questionnaires	PEST,	PASE	&	EARP.	During	clinical	evaluation	a	detailed	history	was	taken	


















In	 the	 initial	 study,	 a	 new	 questionnaire	 was	 developed	 via	 three	 different	methods,	 namely	 the	
CONTEST	(addition	of	questions),	the	CONTEST-w	(weighted	version	using	logistic	regression)	and	the	
CONTEST-jt	 (adding	a	manikin).7	 The	questionnaires	 consisted	of	 the	best	performing	 items	of	 the	
individual	screeningtools	PEST,	PASE	and	ToPAS.	 	The	CONTEST	consists	of	eight	questions	and	the	
total	 score	 is	 the	 sum	of	 all	 individual	positively	 answered	questions	 (range	0-8),	 the	 cut	off	 for	 a	
positive	questionnaire	was	 set	at	 four	 in	 the	development	 cohort.	 The	CONTEST-w	consists	of	 the	



















Sensitivity,	 specificity	and	area	under	 the	curve	 (AUC)	were	calculated	 for	all	 three	versions	of	 the	
CONTEST	and	the	PEST,	PASE	&	EARP	using	STATA	14.	Additionally,	we	did	a	subgroup	analysis	in	which	
we	approximated	the	patient	selection	of	the	CONTEST	study,	meaning	only	patients	with	at	least	one	
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Table 1 Overview of the different versions of the CONTEST questionnaire, including  substitutes used in the 
SENSOR study




Substitutes in the 
SENSOR
PEST 4 Have you had pain in your heel? Weight 2
PEST 5 Have you had a finger or toe that 
was completely swollen and painful 
for no apparent reason?
PASE 3 My back hurts
PASE 4 My joints become swollen
PASE 5 My joints feel “hot”
TOPAS 2A Have you ever noticed any of these 
changes in your fingernails: pits in 
the nails as shown in Figure 1
Weight 5 PEST 3. Do your 
fingernails or toenails 
have holes or pits?
TOPAS 2B Have you ever noticed any of these 
changes in your fingernails: lifting of 
the nail from the nailbed as shown 
in Figure 2
Assessment of the 
nail photographs by a 
dermatologist
TOPAS 7 Have you ever had neck pain lasting 
at least 3 months that was not 
injury related?
PEST mannikin: Positive 









a	 rheumatologist	 in	 17	 cases.	 Within	 the	 PsA	 cases	 11	 patients	 (64.7%)	 presented	 solely	 with	
peripheral	arthritis.	Five	cases	(29.4%)	of	axial	PsA	were	diagnosed	and	one	patient	(5.9%)	presented	



















Sensitivity,	 specificity	and	area	under	 the	curve	 (AUC)	were	calculated	 for	all	 three	versions	of	 the	
CONTEST	and	the	PEST,	PASE	&	EARP	using	STATA	14.	Additionally,	we	did	a	subgroup	analysis	in	which	
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When	 comparing	 the	 performance	 of	 the	 CONTEST	 with	 the	 already	 existing	 screeningtools,	
differences	can	be	shown.	First	of	all,	where	the	AUC	of	the	CONTEST	questionnaires	are	lower	than	
the	AUC	of	the	other	three	screeningtools	in	the	development	studies,	this	difference	is	not	as	obvious	





For	 the	subgroup	analysis,	where	patients	were	selected	 in	approximately	 the	same	way	as	 in	 the	
initial	development	study,	227	patients	were	available	as	they	had	a	positive	PEST	(value	≥3)	and/or	
PASE	 (value≥47).	 	 AUC	was	 the	 same	 for	 all	 three	 versions	 of	 the	 contest	 at	 0.60.	 Sensitivity	was	
comparable	 between	 the	 CONTEST	 and	 the	 CONTEST-jt	 versions,	with	 0.64	 and	 0.62	 respectively,	
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Mean Age, years (±SD) 55.9 (14.0) 47.4 (10.7) 58.0 (12.3)
Male sex, n (%) 216 (51.4) 8 (47.1) 17 (47.2)
Body Mass Index, mean (±SD) 27.8 (4.8) 27.9 (6.2) 30.0 (4.1)
Median Psoriasis Symptom Duration, years (IQR) 15 (8-30) 15 (4-30) 20 (11-37)
Psoriasis Diagnosis by Dermatologist, n (%) 302 (71.9) 13 (76.5) 31 (86.1)
Nail psoriasis, n (%) 64 (15.2) 5 (29.4) 2 (5.6)
PASI, median (IQR) 2.2 (1-4) 3 (1.3-4) 3.1 (1.7-4.4)
Median MSC Symptom Duration, years (IQR)  
                                                                              Joints 8 (4-14) 12.5 (2-23) 10 (5-25)
Lower Back 12 (5-25) 18 (9-25) 33 (14-41)
LEI, median (IQR) 0 (0-0) 0 (0-1) 1 (1-2)
MASES, median (IQR) 0 (0-0) 0 (0-3) 2 (0-3)
*Axial manifestations & arthritis are the patients who were diagnosed as having PsA by the rheumatologist. 
Enthesitis are the patients who would have a diagnosis of PsA based on the CASPAR criteria. Established 
PsA are the patients already diagnosed with PsA at the beginning of the study and psoriasis patients are the 





the	 development	 and	 this	 validation,	 the	 discriminative	 properties	 differed.	 In	 our	 primary	 care	
setting,	sensitivity	was	considerably	lower	whereas	specificity	was	higher	for	all	three	versions.	When	
we	approximated	the	patient	selection	of	 the	development	 (i.e.	 those	with	a	positive	PEST	and/or	




this	 is	 at	 the	 expense	 of	 the	 specificity	 (0.33,	 0.37,	 0.43	 respectively)	 it	 would	 result	 in	 a	 lot	 of	
unnecessary	referrals.	
The	developers	of	the	CONTEST	aimed	to	develop	a	questionnaire	with	considerably	improved	
performance	 than	 the	 previously	 developed	 individual	 screening	 questionnaires.	 Although	 the	
performance	 in	 the	 initial	 development	 study	 seemed	 to	 be	 better	 than	 the	 performance	 of	 the	








questions	and	were	 therefore	able	 to	give	a	good	estimation	of	 its	performance	 in	a	primary	care	
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Over	the	years	 it	has	become	more	and	more	apparent	that	early	recognition	of	SpA	 is	 important.	
However,	early	signs	of	 inflammatory	SpA	resembles	those	of	aspecific	 low	back	pain	or	 joint	pain.	



































Over	the	years	 it	has	become	more	and	more	apparent	that	early	recognition	of	SpA	 is	 important.	
However,	early	signs	of	 inflammatory	SpA	resembles	those	of	aspecific	 low	back	pain	or	 joint	pain.	


































The	 prevalence	 of	 SpA	 in	 patients	 with	 IBD	 was	 established	 with	 a	 systematic	 review	 and	meta-
analysis.	We	 found	 a	 pooled	 prevalence	 of	 11%	 for	 sacroiliitis	 and	 3%	 for	 its	 subtype	 ankylosing	
spondylitis.	The	pooled	prevalence	for	peripheral	arthritis	was	found	to	be	14%.		






part	 of	 the	 AppSpA	 study	we	 therefore	 invited	 general	 practitioners	 to	 complete	 a	 questionnaire	
regarding	inflammatory	symptoms	and	features	of	SpA.	We	showed	that	almost	60%	of	GPs	did	not	
recognize	half	of	the	symptoms	indicative	for	inflammatory	peripheral	joint	disease,	for	inflammatory	












generalizability	of	our	 results.	The	 following	part	of	 the	discussion	will	 focus	on	 several	aspects	of	






















study	was	 about	musculoskeletal	 complaints.	 Although	we	 explicitly	 asked	 patients	 to	 participate	










the	 participants	 was	male.	Most	 studies	 show	 an	 equal	 distribution	 between	males	 and	 females,	





outcome	 in	 the	 SENSOR	 study	was	 a	 diagnosis	 of	 PsA,	which	was	made	 by	 a	 rheumatologist.	 	 As	
enthesitis	 is	 still	 very	difficult	 to	diagnose,	we	used	 the	CASPAR	criteria	 to	diagnose	PsA	based	on	
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the	 participants	 was	male.	Most	 studies	 show	 an	 equal	 distribution	 between	males	 and	 females,	





outcome	 in	 the	 SENSOR	 study	was	 a	 diagnosis	 of	 PsA,	which	was	made	 by	 a	 rheumatologist.	 	 As	
enthesitis	 is	 still	 very	difficult	 to	diagnose,	we	used	 the	CASPAR	criteria	 to	diagnose	PsA	based	on	
enthesitis.	 In	 the	 CASPAR	 critera	 enthesitis	 is	 stated	 as	 an	 entry	 criteria,	 so	 patients	 with	 solely	
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enthesitis	 (without	 arthritis	 or	 axial	 involvement)	 could	 classify	 as	 PsA.	However,	when	 a	 patients	
would	classify	as	having	enthesitis	is	not	defined.	This	is	why	we	chose	to	combine	clinical	evaluation	
(LEI/MASES)	 with	 ultrasound	 findings.	 In	 this	 way	 we	 tried	 to	 diagnose	 enthesitis	 as	 objective	 as	
possible.	In	addition,	the	CASPAR	criteria	are	classification	criteria	and	not	diagnostic	criteria,	so	one	
could	say	they	are	not	to	be	used	to	diagnose	a	disease.	This	is	why	we	mentioned	the	prevalence	of	
enthesitis	 separately	 in	 our	 prevalence	 study.	 During	 our	 study	we	 found	 that	many	 participating	
rheumatologists	 found	 it	 difficult	 to	 diagnose	 PsA	 solely	 based	 on	 enthesitis,	 as	 it	 seems	 quite	
unspecific	and	there	is	still	so	much	unknown.		
































education	 of	 GPs.	 However,	 guidelines	 and	 education	 alone	 does	 not	 seem	 to	 be	 sufficient.	 Two	
reviews,	 of	which	 one	was	 specifically	 aimed	 at	 inflammatory	 arthritis,	 showed	 that	 referral	 from	
primary	to	secondary	care	could	also	be	 improved	via	the	use	of	self-administered	questionnaires,	
referral	sheets	or	triage	by	a	specialist	in	a	primary	care	setting.3,4	
Looking	 into	 self-administered	 questionnaires	 or	 referral	 sheets,	 the	 screeningtools	 for	 PsA	 as	





themselves	 with	 axial	 manifestations.	 Multiple	 referral	 tools	 have	 been	 developed	 for	 axial	 SpA,	














Besides	 the	 GPs,	 medical	 specialists	 should	 also	 be	 involved	 when	 improving	 awareness.	 All	 IBD	
patients	will	be	treated	by	a	gastroenterologist,	while	a	certain	part	of	the	psoriasis	patients	(e.g.	the	
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Besides	 the	 GPs,	 medical	 specialists	 should	 also	 be	 involved	 when	 improving	 awareness.	 All	 IBD	
patients	will	be	treated	by	a	gastroenterologist,	while	a	certain	part	of	the	psoriasis	patients	(e.g.	the	
more	 severe	psoriasis	or	psoriasis	with	a	 lot	of	 comorbidity)	will	 be	 treated	by	a	dermatologist.	A	
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recent	 study	 showed	 that	 the	 knowledge	 about	 in	 this	 case	 axial	 SpA	was	 insufficient	 in	medical	
specialists,	 leading	to	diagnostic	delay.14	To	 increase	awareness	 in	this	group,	certain	strategies	for	
GPs	could	also	be	used,	like	education	and	the	use	of	screeningtools.	As	in	a	primary	care	setting,	the	
PEST	could	also	be	used	in	dermatology	practice.	Another	way	to	improve	care	for	psoriasis	and	IBD	
















prevalence	 of	 musculoskeletal	 complaints.	 It	 may	 be	 more	 efficient	 to	 add	 information	 about	
musculoskeletal	complaints	and	SpA	to	the	information	folders	of	psoriasis	and	IBD.	In	that	way,	when	
patients	are	diagnosed	with	psoriasis	or	IBD,	they	will	receive	an	information	folder	about	their	disease	












Over	 the	 years	 a	 lot	 of	 different	 classification	 criteria	 for	 SpA	have	been	developed.16-20	 The	most	
recent	set	of	criteria	are	the	ASAS	criteria	developed	around	2010.19,20	When	using	these	criteria	a	
distinction	is	made	between	axial	and	peripheral	SpA,	based	on	the	most	predominant	symptoms.	A	






developed	 and	 although	 SpA	 in	 IBD	 occurs	 as	 frequently,	 no	 screeningtools	 are	 available.	 As	 all	




















For	 both	 the	 screeningtools	 for	 PsA	 as	 the	 referral	 tools	 for	 axial	 SpA,	 multiple	 tools	 have	 been	
developed	over	the	years.	Most	of	these	tools	have	also	been	validated	in	different	cohorts.	However,	
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sacroiliitis)	 or	 peripheral	 symptoms	 (arthritis,	 enthesitis,	 dactylitis).	 Patients	 with	 psoriasis	 or	













eligible	 and	willing	 to	 participate.	 Participating	 patients	 completed	 a	 set	 of	 questionnaires	 before	









Chapter	 3	 describes	 the	 ultrasound	 findings	 in	 the	 patients	 who	 were	 found	 to	 clinically	 have	
enthesitis.	 In	 the	 CASPAR	 criteria	 enthesitis	 is	 stated	 as	 an	 entry	 criteria,	 leading	 to	 the	 fact	 that	
patients	with	enthesitis	could	classify	as	PsA.	The	problem	is	that	the	definition	of	enthesitis	 is	not	
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We	defined	 clinically	 relevant	 inflammation	 as	 active	 inflammation	 on	 ultrasound	 (positive	 power	
Doppler	 signal	 or	 in	 case	 of	 the	 plantar	 fascia	 increased	 thickness)	 in	 combination	 with	 a	 tender	
enthesis	at	the	same	site	during	clinical	examination.	Forty	patients	(36%)	of	the	patients	had	clinically	
relevant	inflammation.	The	most	common	sites	were	the	knee	and	the	plantar	aponeurosis.	Structural	





of	 axial	 and	 peripheral	 manifestations	 of	 SpA	 in	 patients	 with	 IBD	 as	 described	 in	 chapter	 4.	 An	
extensive	 search	 strategy	 was	 set	 up	 in	 collaboration	 with	 the	 medical	 library,	 leading	 to	 4845	
potentially	relevant	articles.	After	screening	the	titles	and	abstracts	and	subsequently	the	full	text	of	
these	papers,	60	were	relevant	and	were	included.	Quality	assessment	of	the	included	articles	showed	
moderate	 overall	 quality.	 With	 regard	 to	 axial	 manifestations	 (i.e.	 sacroiliitis	 and	 ankylosing	
spondylitis),	53	papers	reported	on	the	prevalence	in	IBD	patients.	The	pooled	prevalence	was	11%	







musculoskeletal	 complaints	 before	 they	 are	 diagnosed	with	 SpA.	 In	 chapter	 5	we	 looked	 into	 the	
burden	of	these	musculoskeletal	complaints	in	patients	with	IBD.	We	set	up	a	cross-sectional	survey	
among	 patients	 diagnosed	 with	 IBD	 between	 18	 and	 55	 years	 of	 age.	 They	 completed	 different	
questionnaires	regarding	their	MSC,	but	also	on	quality	of	life,	disability	and	work	participation	and	
productivity.	 In	 total,	 338	 patients	 completed	 the	 questionnaires,	 of	 whom	 45.6%	 suffered	 from	











its	 impact.	We	know	that	early	recognition	of	SpA	 in	these	patients	 leads	to	earlier	 treatment	and	
thereby	 better	 outcomes	 in	 the	 longterm.	 To	 enhance	 this	 early	 recognition,	 there	 should	 be	
awareness	for	SpA.	 In	chapter	6	we	describe	the	results	of	the	AppSpA	study,	which	was	set	up	to	
assess	 the	 current	 awareness	 for	 SpA	 in	 both	 general	 practitioners	 and	 patients	 themselves.	We	
developed	a	survey	for	GPs	to	complete,	focussing	on	recognition	of	inflammatory	symptoms	and	SpA-
specific	 features.	 Patients’	 awareness	 was	 also	 assessed	 with	 a	 survey.	 We	 invited	 949	 GPs	 to	
participate,	of	whom	312	returned	the	survey	(response	rate	32.9%)	of	whom	185	GPs	completed	the	
survey.	With	regard	to	the	recognition	of	signs	of	inflammatory	pain,	especially	classic	symptoms	like	




we	 saw	 that	 less	 than	 half	 of	 the	 patients	 with	 psoriasis	 or	 IBD	 was	 aware	 of	 the	 possibility	 of	
developing	 SpA,	 namely	 42.6%.	 If	 they	 were	 aware	 of	 this	 possibility,	 most	 of	 them	 gained	 this	
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awareness	for	SpA.	 In	chapter	6	we	describe	the	results	of	the	AppSpA	study,	which	was	set	up	to	
assess	 the	 current	 awareness	 for	 SpA	 in	 both	 general	 practitioners	 and	 patients	 themselves.	We	
developed	a	survey	for	GPs	to	complete,	focussing	on	recognition	of	inflammatory	symptoms	and	SpA-
specific	 features.	 Patients’	 awareness	 was	 also	 assessed	 with	 a	 survey.	 We	 invited	 949	 GPs	 to	
participate,	of	whom	312	returned	the	survey	(response	rate	32.9%)	of	whom	185	GPs	completed	the	
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we	 saw	 that	 less	 than	 half	 of	 the	 patients	 with	 psoriasis	 or	 IBD	 was	 aware	 of	 the	 possibility	 of	
developing	 SpA,	 namely	 42.6%.	 If	 they	 were	 aware	 of	 this	 possibility,	 most	 of	 them	 gained	 this	

















screen	 for	 PsA.	 It	 might	 however	 be	 more	 useful	 to	 only	 screen	 patients	 with	 musculoskeletal	
complaints,	due	to	the	fairly	low	prevalence	of	PsA	in	primary	care.	
	
As	 shown	 in	 chapter	 7	 and	 various	 other	 validation	 studies,	 the	 existing	 screeningtools	 perform	
moderately.	 This	 is	 why	 the	 CONTEST	 group	 developed	 a	 new	 screeningtool	 based	 on	 the	 best	
performing	items	of	the	previous	screeningtools.	In	chapter	8	we	assessed	the	additional	value	of	this	
CONTEST	 questionnaire	 in	 a	 primary	 care	 setting.	 Data	 from	 the	 SENSOR	 study	was	 used	 and	we	
calculated	sensitivity,	specificity	and	area	under	the	curve	for	the	various	versions	of	the	CONTEST.	
For	 this	 analysis,	 473	 psoriasis	 patients	 without	 PsA	 were	 available.	 The	 AUC	 of	 the	 CONTEST	
questionnaires	 ranged	 between	 0.67-0.69	 and	 sensitivities	 between	 0.30-0.51	 in	 our	 primary	 care	













Hoofdstuk	 1	 vormt	 de	 algemene	 introductie	 van	 dit	 proefschrift.	 Spondylarthopathie	 (SpA)	 is	 een	
overkoepelende	 term	 voor	 een	 groep	 van	 inflamamtoire	 reumatische	 aandoeningen.	Het	 kan	 zich	
presenteren	 met	 axiale	 symptomen	 (lage	 rugpijn,	 sacroiliitis)	 of	 perifere	 symptomen	 (artritis,	
enthesitis,	 dactylitis).	 Patienten	 met	 psoriasis	 of	 inflammatoire	 darmziekten	 (IBD)	 hebben	 een	
verhoogd	risico	op	het	ontwikkelen	van	SpA,	vanwege	de	grote	overlap	in	de	pathogenese	van	deze	














vragenlijsten	 in	 voordat	 ze	 klinisch	 geevalueerd	 warden.	 De	 klinische	 evaluatie	 bestond	 uit	 een	
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definitie	 van	klinisch	 relevante	enthesitis	was	een	combinatie	 van	actieve	 inflammatie	op	de	echo	
(positief	power	Doppler	signaal	of	in	het	geval	van	de	fascia	plantaris	verdikking)	in	combinatie	met	
een	pijnlijke	enthesis	op	dezelfde	plek.	Volgens	deze	definitie	hadden	40	patienten	(36%)	een	klinisch	








werd	 een	 uitgebreide	 zoekstrategie	 opgezet,	 die	 leidde	 tot	 een	 total	 aantal	 van	 4845	 potentieel	











We	 weten	 nu	 dat	 SpA	 relatief	 vaak	 voorkomt	 bij	 patienten	 met	 IBD.	 Het	 meerendeel	 van	 deze	
patienten	zal	eerst	last	krijgen	van	musculoskeletale	klachten	voor	ze	gediagnosticeerd	worden	met	
SpA.	In	hoofdstuk	5	kijken	we	naar	de	last	van	deze	musculoskeletale	klachten	bij	patienten	met	IBD.	
We	hebben	 een	 cross-sectionele	 studie	 opgezet	 gebaseerd	 op	 vragenlijsten	 bij	 patienten	met	 IBD	
tussen	 de	 18	 en	 55	 jaar.	 De	 vragenlijsten	 gingen	 over	 het	 al	 dan	 niet	 aanwezig	 zijn	 van	
musculoskeletale	klachten,	maar	ook	over	kwaliteit	van	leven	en	het	werkend	leven.	In	total	hebben	
338	de	vragenlijsten	 ingevuld,	van	wie	45.6%	de	ziekte	van	Crohn	(CD)	had	en	45%	colitis	ulcerosa	











In	 het	 eerste	 gedeelte	 van	 dit	 proefschrift	 hebben	 we	 de	 prevalentie	 van	 SpA	 in	 risicogroepen	
vastgesteld	en	de	impact	hiervan.	We	weten	dat	vroegherkenning	van	deze	patienten	leidt	tot	eerdere	
behandeling	en	daarmee	tot	betere	uitkomsten	op	de	 lange	 termijn.	Om	deze	vroegherkenning	 te	
verbeteren,	moet	er	awareness	komen	voor	SpA.	In	hoofdstuk	6	beschrijven	we	de	resultaten	van	de	
AppSpA	studie	welke	opgezet	is	om	de	huidige	awarenesss	voor	SpA	bij	huisartsen	en	patienten	met	
psoriasis	 of	 IBD	 in	 kaart	 te	 brengen.	 We	 ontwikkelden	 een	 enquete	 voor	 huisartsen,	 gericht	 op	




zoals	 ochtendstijfheid	 en	 verbetering	 van	 de	 klachten	 door	 NSAIDs	 herkend	 werden.	 Andere	
symptomen	 zoals	 verbetering	 van	 de	 pijn	 bij	 beweging	werden	 slecht	 herkend.	 Bijna	 60%	 van	 de	
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Een	 van	 de	 mogelijkheden	 om	 vroegherkenning	 in	 de	 hand	 te	 werken	 is	 het	 inzetten	 van	
screeningtools.	Voor	PsA	zijn	er	diverse	screeningtools	ontwikkeld,	het	meerendeel	in	de	tweede	lijn.	
In	Nederland	hebben	we	echter	een	uitgebreid	eerstelijnszorg	system,	waardoor	deze	hulpmiddelen	
het	 beste	 in	 de	 eerste	 lijn	 ingezet	 kunnen	worden.	 In	hoofdstuk	7	 hebben	we	de	werking	 van	de	
bestaande	screeningtools	onderzocht	in	een	eerstelijns	populatie.	Voor	dit	gedeelte	hebben	we	data	











Zoals	 uit	 hoofdstuk	 7	 blijkt,	 hebben	 de	 bestaande	 screeningtools	 geen	 ideale	 sensitiviteit	 en	
specificiteit.	 Om	 deze	 reden	 heeft	 de	 CONTEST	 studiegroep	 een	 nieuwe	 screeningtool	 opgezet	
gebaseerd	uit	de	best	onderscheidende	vragen	van	bestaande	screeningtools.	In	hoofdstuk	8	hebben	
we	bekeken	of	deze	nieuwe	vragenlijst	meerwaarde	heeft	ten	opzichte	van	de	eerder	ontwikkelde	
vragenlijsten	 in	 de	 eerste	 lijn.	 Data	 van	 de	 SENSOR	 studie	 werd	 gebruikt	 en	 we	 berekenden	
sensitiviteit,	 specificiteit	 en	 area	 under	 the	 curve	 (AUC)	 voor	 de	 diverse	 versies	 van	 de	 CONTEST	
vragenlijst.	Voor	deze	analyse	hadden	we	473	patienten	 zonder	PsA	beschikbaar.	De	AUC	voor	de	
CONTEST	versies	varieerde	 tussen	de	0.67	en	0.69.	De	 sensitiviteit	 in	onze	eerstelijnspopulatie	 lag	
tussen	de	0.30	en	0.51,	met	een	specificiteit	tussen	de	0.74	en	0.86.	Als	we	kijken	naar	sensitiviteit,	
doen	zowel	de	PEST	(0.68)	als	de	PASE	(0.66)	en	de	EARP	(0.87)	het	beter	dan	de	CONTEST,	maar	qua	
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